

DEPARTMENT OF NEUROLOGY SERIES OF REPORTS NO 85, 2006

CORINA PENNANEN

Brain Atrophy in Mild Cognitive Impairment: MRI volumetric and voxel-based method study

Doctoral dissertation

To be presented with assent of the Medical Faculty of the University of Kuopio for public examination in Auditorium, Mediteknia building, University of Kuopio, on Friday 24th November 2006, at 12 noon

Department of Neurology,
University of Kuopio

Department of Neurology
Kuopio University Hospital

Department of Radiology,
Kuopio University Hospital



KUOPIO 2006

- Distributor:** Department of Neurology
University of Kuopio
P.O. Box 1627
FI-70211 Kuopio
FINLAND
Tel.: +358 17 162 682
Fax.: +358 17 162 048
- Author's address:** Department of Neurology
University of Kuopio
P.O. Box 1627
70211 KUOPIO
FINLAND
Tel.: +358 46 810 7444
E-mail: corina.pennanen@uku.fi
cpennanen@gmail.com
- Supervisor:** Professor Hilikka Soininen, MD., Ph.D.
Department of Neurology University of Kuopio and
Kuopio University Hospital
- Reviewers:** Professor Nick Fox, Ph.D.
The Dementia Research Centre,
Institute of Neurology, University College London and
National Hospital for Neurology and Neurosurgery, Queen Square,
London, United Kingdom
- Per Julin, MD, PhD
Senior Research Scientist
Discovery Medicine/Neuroscience
AstraZeneca R&D Södertälje
SE-151 85 Södertälje, Sweden
- Opponent:** Professor Lars-Olof Wahlund, MD., Ph.D.
Division of Clinical Geriatric, Neurotec,
Karolinska Institute, Huddinge University Hospital,
Huddinge, Sweden

ISBN 951-781-377-5
ISBN 951-27-0215-0 (PDF)
ISSN 0357-6043

Kopijyvä
Kuopio 2006
Finland

Pennanen, Corina. Brain Atrophy in Mild Cognitive Impairment: MRI volumetric and voxel-based method study. Series of reports, No. 85, Department of Neurology, University of Kuopio, 2006, 93 p.
ISBN 951-781-377-5
ISBN 951-27-0215-0 (PDF)
ISSN 0357-6043

ABSTRACT

Background: Mild cognitive impairment (MCI), a heterogeneous status, has gained increased interest from clinicians and researchers, because it has been shown to represent a transitional stage between normal ageing and very early Alzheimer's disease (AD). Neuroimaging data, genetic findings, biological markers and neuropsychological tests have been evaluated as predictors of conversion from MCI into dementia, most commonly AD. Magnetic resonance imaging (MRI) using volumetric measurements of regions of interest (ROI), as well as more advanced imaging techniques, such as voxel based morphometry (VBM), increasingly used in studying AD patients, now were engaged in studying MCI subjects to determine which of them are to convert into dementia. Apolipoprotein E (APOE) allele $\epsilon 4$ is the most consistently confirmed genetic risk factor for Alzheimer's disease (AD). *Objectives:* By using MRI volumetric studies to compare MCI subjects with controls and patients with mild AD, we intended to determine whether the entorhinal atrophy precedes hippocampal atrophy in AD. Moreover, with the help of VBM we wanted to map the gray matter loss in the entire brains of MCI subjects. As previous studies have suggested that the APOE genotype can influence the size of various brain structures, our objective was to investigate the difference in the morphologic expression of MCI in subjects carrying the APOE allele $\epsilon 4$ compared to the noncarriers using VBM. Finally we intended to conduct a follow-up study and determine the predictors for conversion into AD.

Results: In the ROI-volumetric MRI study, we showed that the entorhinal volume loss predominated over the hippocampal volume loss in MCI, whereas more pronounced hippocampal volume loss appeared in mild AD. Using VBM in MCI subjects vs. controls, the greatest atrophy was found in the right hippocampus-amygdala region and in the right hippocampal tail and thalamus, while less extensive areas of atrophy were detected in the right superior temporal gyrus, the left thalamus, the left inferior temporal gyrus, and the left anterior cingulate gyrus. The extent of the atrophy was significant in the medial temporal lobe, on the right side. Between cases heterozygous for the APOE $\epsilon 4$ and those who were APOE $\epsilon 4$ noncarriers, only the right parahippocampal gyrus, with entorhinal cortex included, reached a level of statistical significance. In cases homozygous for the $\epsilon 4$ allele vs. noncarriers, the greatest atrophy was located in the right amygdala followed by the right parahippocampal gyrus, the left amygdala and the left medial dorsal thalamic nucleus. During the follow-up time of about 34 months, 21.7 % of the MCI subjects converted into dementia, with 15% developing AD. The right hippocampal and entorhinal volumes significantly predicted the conversion into AD.

Conclusions: In the present study, the ERC atrophy appears to be dominant over the hippocampal atrophy in MCI, whereas more pronounced hippocampal atrophy was seen in mild AD. The VBM method revealed involvement of other brain areas, in addition to the MTL, in the state of MCI. The vast majority of the brain atrophy observed in individuals with MCI appears to be due to the small group homozygous for the $\epsilon 4$ allele. The atrophy of the MTL seen in the baseline, predicted the conversion to AD during a follow-up of 34 months, while the severity of cognitive impairment, the white matter lesions or the APOE provided no additional contribution to the prediction of conversion of MCI to AD.

National Library of Medicine Classification: QU 470, QZ 180, WL 141, WL 314, WM 220, WN 185, WT 155

Medical Subject Headings: Alleles; Alzheimer Disease/physiopathology; Amygdala/pathology; Apolipoproteins E/genetics; Atrophy; Brain/pathology; Cognition Disorders/genetics; Dementia/physiopathology; Entorhinal Cortex; Hippocampus/physiopathology; Magnetic Resonance Imaging/methods

To Jussi, Carmen and Robert

ACKNOWLEDGEMENTS

This thesis is based on the work carried out in the Department of Neurology, University of Kuopio and Kuopio University Hospital, and the MRI unit of the Department of Clinical Radiology, Kuopio University Hospital, during the years 2000-2006. Part of this study was done in close collaboration with the Laboratory of Epidemiology, Neuroimaging & Telemedicine (LENITEM), IRCCS San Giovanni di Dio-FBF, Brescia, Italy. This study is also collaboration with the Department of Public Health and General Practice, University of Kuopio, and the National Public Health Institute, Helsinki. The study is part of a very large project aimed to investigate features of memory impairment and dementia. As for me, 2 weeks after stabilising in Finland, I was given different tasks to do in the Neurology Department and MRI unit, getting trained and gaining trust from Prof. Hilikka Soininen and co-workers for a larger work project, which further on brought me to this point of my thesis.

I would like to thank warmly all the people who have contributed to this work. In particular, I want to thank:

Professor Hilikka Soininen, for introducing me to the vast field of Alzheimer's disease and mild cognitive impairment, and giving me the opportunity to start the studies with MRI volumetry applied on this medical field. She gave me continuous support and excellent guidance whenever I needed it, with mother's kindness and professor's seriousness. This, during years of so many different life tasks including raising children and receiving clinical achievements in a foreign language, helped me to believe that it is still possible to climb on to the high mountaintop of a doctoral thesis project work.

Professor Nick Fox, PhD and Per Julin, MD, PhD, for accepting to be the official reviewers of this thesis, for their intensive work to review the dissertation in a tight time schedule and for their constructive suggestions to improve the manuscript.

Mikko Laakso, the "Big Daddy M" as he used to call himself, with his humoristic sarcasm and criticism, I managed to overtake the obstacles one may encounter when writing scientific articles. Thank you Mikko, I learned a lot from you and your strong and confident scientific writing style, which I always admired.

Kaarina Partanen, Päivi Hartikainen, again Mikko Laakso and especially Leena Jutila for precious teaching sessions on manually tracing medial temporal lobe structures.

Miia Kivipelto, the always happy and at the same time very ambitious scientist and medical doctor, the friendliest person who I worked with, for her building-up concerns in the matter of scientific work. Not the least, my thanks for her stimulating push to use the Finnish language, with the help of which I got courage to open my mouth in one of the most difficult foreign language later on, the key to have my licence to practice medicine recognised in Finland.

Mervi Könönen, for her always prompt support and help in various technical questions.

Maija Pihlajamäki, for her helpful tutoring at the very beginning of my research work.

Cristina Testa, for voxel-based morphometry analysis done in Italy on our data, for her friendly and professional help and always prompt replies to my questions, though thousands of kilometres prevented us meeting personally.

Furthermore, I am grateful to my co-workers Susanna Tervo, Tuomo Hänninen, Merja Hallikainen, Matti Vanhanen, Aulikki Nissinen, Eeva-Liisa Helkala, Pauli Vainio, Ritva Vanninen, Giovanni Frisoni, Roberta Rossi, Marina Boccardi, Anne Hämäläinen, Mia and Tero Tapiola for a job well done.

Pirjo Halonen, from the Computing Centre of the University of Kuopio, for her clear advices and excellent assistance with statistical analyses. Ewen Macdonald, for providing an urgent English checking for my thesis.

Warm thank to Esa Koivisto, for computer assistance and to the personnel of the Department of Neurology from the University of Kuopio: Nilla Nykänen, Tuija Parsons, Mari Tikkanen and especially Sari Palviainen, for their help in all the formalities, which I had to deal with during all this time. The people volunteering for the study, particularly the patients, without whom none of this would have ever been possible.

Liu Yawu, for excellent advice and constructive comments, for sharing his scientific experience, whenever I called him and asked for assistance.

All my colleagues and friends from medical fields, also others than neurology, as well as from other fields of life, for their support and cheering time that helped me to go on.

To all my relatives who always gave me support and were close to me even though thousands of miles separated us; and I would like to honor the memory of my mother-in-law, who gave me feeling of family in the country far away from my homeland. I owe my dearest thanks to my aunt Paula Smarandescu, for her never-ending support.

To my grandmother "Mamaie" Eugenia Vranceanu and my mother Mioara Krachtus, for their everlasting love that have given me strength to go on, both in joy and in sorrow.

To my dear husband Jussi, for his support with love, understanding and care, which was always overwhelming me, since the first day we met. Your presence and help was invaluable during the process of this work.

Finally, I dedicate this work in addition to my dear husband Jussi, also to my wonderful children, my three-year-old daughter Carmen and my one-year-old son Robert, both of them will always be the joy of my life. The priority that they have in my life did postpone - and will always do so - other duties, including the finalising of this thesis; nevertheless, they are the source of energy for receiving and finalising all the duties that are meant to be part of my life.

This study was financially supported by the University of Kuopio, by the Aging Program of the Health Research Council of the Academy of Finland and the EVO grants 5510, 5152, and 5772720, and Nordic Center of Excellence in Neurodegeneration, and by the A.A. Laaksonen grant of the Pohjois-Savo Kulttuurirahasto. The study was also partly supported by FinnWell program of the National Technology Agency of Finland and EU Regional funding, 70075/05.

Thank you all!

Kuopio, November 2006


Corina Pennanen

ABBREVIATIONS

AACD	Age-associated cognitive decline
AAMI	Age-associated memory impairment
AD	Alzheimer's disease
ANCOVA	Analysis of covariance
ANOVA	Analysis of variance
ApoE	Apolipoprotein E protein
APOE	Apolipoprotein E gene
BBSI	Brain boundary shift integral
BSI	Boundary shift integral
CDR	Clinical Dementia Rating
CERAD	Consortium to Establish Registry for Alzheimer's Disease
CI	Confidence interval
CMRgl	Cerebral metabolic rates for glucose
CSF	Cerebrospinal fluid
DNA	Deoxyribonucleic acid
EADC	European Alzheimer's Disease Consortium
EEG	Electroencephalography
ERC	Entorhinal cortex
FLAIR	Fluid-attenuated inversion-recovery
GDR	Global Deterioration Scale
GM	Gray matter
HC	Hippocampus
HR	Hazard ratio
ICA	Intracranial area
ICD 10	International Classification of Diseases
MCI	Mild cognitive impairment
MMSE	Mini-Mental Status Examination
MRI	Magnetic resonance imaging
MTL	Medial temporal lobe
MCADRC	Mayo Clinic Alzheimer's Disease Research Center
NFT	Neurofibrillary tangle
NIA	National Institute of Aging-Reagan Institute
NINCDS-ADRDA	National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association
PET	Positron emission tomography
PD	Proton density
ROI	Region of interest
SD	Standard deviation
SPSS	Statistical package for social sciences
T	Tesla
T1	Longitudinal relaxation
T2	Transverse relaxation
TE	Time of echo
TR	Time of repetition
VBM	Voxel-based morphometry
VBSI	Ventricular boundary shift integral
WAIS-R	Wechsler Adult Intelligence Scale-Revised
WM	White matter
WML	White matter lesion

LIST OF ORIGINAL PUBLICATIONS

This thesis is based on the following original publications referred to in the text by the Roman numerals **I-IV**:

- I.** Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hänninen T, Laakso MP, Hallikainen M, Vanhanen M, Nissinen A, Helkala E-L, Vainio P, Vanninen R, Partanen K, Soininen H. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. *Neurobiol Aging*. 2004;25:303-310.
- II.** Pennanen C, Testa C, Laakso MP, Hallikainen M, Helkala E-L, Hänninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H. A voxel based morphometry study on mild cognitive impairment. *J Neurol Neurosurg Psychiatry*. 2005;76:11-14.
- III.** Pennanen C, Testa C, Boccardi M, Laakso MP, Hallikainen M, Helkala EL, Hänninen T, Kivipelto M, Könönen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H. The effect of apolipoprotein polymorphism on brain in mild cognitive impairment - a voxel-based morphometric study. *Dement Geriatr Cogn Disord* 2006;22:60-66.
- IV.** Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hänninen T, Pihlajamäki M, Laakso MP, Hallikainen M, Hämäläinen A, Vanhanen M, Helkala E-L, Vanninen R, Nissinen A, Rossi R, Frisoni G, Soininen H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. *Neurobiol Aging*. *Accepted for publication*.

CONTENTS

1. INTRODUCTION	15
2. REVIEW OF THE LITERATURE	17
2.1. Aging, Dementia and AD	17
2.1.1. Aging	17
2.1.2. Definition of dementia	17
2.1.3. Alois Alzheimer and Alzheimer's disease	18
2.1.4. Diagnosis of AD	19
2.1.4.1. Clinically	19
2.1.4.2. Neuropathologically	20
2.2. MCI	21
2.2.1. The concept of MCI	21
2.2.2. Diagnosis of MCI	24
2.3. Imaging as an <i>in vivo</i> tool to study the brain	26
2.3.1. Imaging in normal aging brain - a view towards AD	27
2.3.1.1. Structural MRI and gray matter	27
2.3.1.2. A view towards AD	29
2.3.1.3. Structural MRI and white matter	29
2.3.1.4. VBM - gray and white matter	30
2.3.2. Imaging in AD	30
2.3.3. Imaging in MCI	32
2.3.3.1. MRI volumetric studies in MCI	32
2.3.3.2. VBM studies in MCI	34
2.3.4. WMLs and associations with MCI	35
2.3.5. MRI volumetry - a predictor of AD in MCI	36
2.4. APOE and implications in AD and MCI	36
2.4.1. What is APOE?	36
2.4.2. APOE and implications in AD	37
2.4.3. APOE and implications in MCI	38
3. AIMS OF THE STUDY	39
4. SUBJECTS AND METHODS	40
4.1. Subjects	40
4.1.1. Control subjects	40
4.1.2. AD subjects	41
4.1.2. MCI subjects	41
4.2. Imaging of the brain	43
4.2.1. MRI and volumetric studies	43
4.2.1.1. MRI technique for volumetric study	43
4.2.1.2. Determination of volumes	43
4.2.1.3. Measurement of the hippocampal volume	44
4.2.1.4. Measurement of the ERC	45
4.2.1.5. Measurement of the ICA	45
4.2.1.6. Validation studies	45
4.2.2. VBM	45
4.2.2.1. VBM pre-processing	45
4.2.3. Determination of WMLs	48
4.3. Determination of APOE genotype	48
4.4. Statistical analyses	48
4.4.1. MRI volumetric analyses	48
4.4.2. VBM analyses	49

5. RESULTS	51
5.1. Descriptive characteristics	51
5.2. MRI volumetry of hippocampus and ERC in controls, AD subjects and MCI subjects (study I)	52
5.2.1. Comparative volumetric measurements in controls, AD subjects and MCI subjects	52
5.2.2. Discriminant function analyses	54
5.3. VBM analyses in MCI subjects (study II)	57
5.4. VBM analyses in MCI subjects, carriers of APOE ϵ 4 (study III)	59
5.5. Predictors of AD in MCI subjects (study IV)	61
5.5.1. Volumetric measurements at baseline	61
5.5.2. Predictors for conversion to dementia	63
6. DISCUSSION	66
6.1. Study subjects	66
6.2. MRI techniques	66
6.3. ROI- and VBM-based volumetry	68
6.3.1. ROI-based volumetry (study I)	68
6.3.1.1. ROI-based volumetry in AD vs. controls	68
6.3.1.2. ROI-based volumetry in AD vs. MCI	69
6.3.1.3. ROI-based volumetry in MCI vs. controls	69
6.3.2. VBM-based volumetry in MCI vs. controls (study II & III)	70
6.4. Classification and prediction with ROI-based volumetry (study I)	71
6.4.1. Classification of AD and controls	71
6.4.2. Classification of AD and MCI	72
6.4.3. Classification of MCI and controls	72
6.5. APOE and patterns of brain atrophy in MCI (study III & IV)	73
6.6. Prediction of AD in MCI (IV)	75
6.7. Future studies	76
7. CONCLUSIONS	78
8. REFERENCES	79
APPENDIX: ORIGINAL PUBLICATIONS (I-IV)	

1. INTRODUCTION

Dementia is a major cause of disability in the developed countries and places a considerable financial burden on the medical services and health care systems (Erkinjuntti et al., 1986; Hay and Ernst, 1987). An important public health concern of developed countries is aging of the population and the associated increases in the prevalence of various dementias, particularly Alzheimer's disease (AD). The concept of mild cognitive impairment (MCI) refers to a transitional stage between normal ageing and very early AD. MCI, a heterogeneous entity, has been associated with a 10-fold risk for developing dementia, most commonly AD (Petersen et al., 2001 a). AD is one of the most important causes of dementia, and one of the most important reasons for the need for long-term patient care. Therefore, an increasing interest has been focussed on MCI in research into aging-related cognitive disorders, particularly in identifying early AD both for research purposes and as a way to achieve early therapeutic intervention. An annual conversion rate of 6-25% from MCI to AD has been reported, which greatly exceeds that seen in the normal population (1-2%) (Petersen et al., 2001 a). Nevertheless, the epidemiology of MCI is not well known, and some longitudinal population based studies have cast some doubt on the concept of MCI. In the study by Larrieu et al., an annual conversion rate of 8.3% was observed during a five-year period, but again the cases had a tendency to fluctuate, and as many as 40% of MCI cases reverted to normal instead of progressing to dementia during follow up (Larrieu et al., 2002).

Subjects with MCI are characterised by memory complaints, normal general cognitive functions, impaired memory for age, preserved activities of daily living, and they are not demented, but the criteria used for diagnosing MCI have varied in different studies. For this reason, new recommendations for the general criteria for MCI, as published by the Stockholm consensus group, suggesting that the MCI construct should be expanded to include cognitive impairment in other domains such as language, attention, visuospatial skills, perceptual speed, and executive function (Winbland et al., 2004). Several approaches have been attempted to identify among MCI subjects, those who will progress to dementia and AD. The heterogeneity in the use of term has been recognised and independently from the criteria used to diagnose the MCI, predicting factors to AD, such as neuroimaging data, genetic findings, biological markers, and neuropsychological tests have been suggested. For that purpose magnetic resonance imaging (MRI) using volumetric measurements of regions-of-interest (ROI) have been used in many studies. It was shown that the neuropathological changes

occurring in AD develop gradually, first appearing in the entorhinal cortex (ERC) and later progressing to the isocortical areas. Accordingly, studies in vivo on brains such as volumetric MRI indicated that atrophy of the hippocampus and the ERC could be a sensitive indicator of early AD (Jack et al., 1999; Killiany et al., 2002). Moreover, atrophy of the ERC has been suggested to predict AD during its preclinical stage (Killiany et al., 2002). While volumetric studies focus on selected ROIs, voxel-based morphometry (VBM) is able to map the entire brain and to provide a global picture of the studied group of subjects with high reproducibility (Ashburner et al., 2003). Apolipoprotein E (APOE) ϵ 4 allele is the most consistently confirmed genetic risk factor for AD. The APOE ϵ 4 has been associated with the development of AD among individuals with MCI (Petersen et al., 1995) and it is also associated to amnesic-MCI (Lopez et al., 2003). The ϵ 4 carriers show an earlier age of onset and enhanced AD related pathology compared to non-carriers (see for review Lehtovirta et al., 2000) and more pronounced atrophy in the medial temporal lobe (MTL) structures (Juottonen et al., 1998 a; Geroldi et al., 1999; Geroldi et al., 2000). Finally, to conclude what are the neuropsychological, brain imaging and genetic factors that better predict the conversion of MCI subjects to dementia, especially to AD, we need to conduct follow-up studies of MCI subjects.

In this study, brain atrophy was examined using two different imaging methods for volumetric measurements in a preclinical stage of AD so called MCI, and the predicting value of the MTL atrophy for developing AD, together with other features characteristic for AD were examined in MCI subjects.

2. REVIEW OF THE LITERATURE

2.1. Aging, Dementia and AD

2.1.1. Aging

Successful aging can be accounted for surviving and functioning. A decline in cognitive functioning that affects on the daily life will conduct towards dementia. Therefore, bringing up the subject of AD, dementia or mild cognitive impairment, one would first stop on the condition of aging, with different descriptions: usual, normal, and successful (Rowe and Kahn, 1987). Unfortunately, forgetfulness is present to some degree, from time to time in almost all of us. Memory function as measured by delayed recall of newly learned material is not clearly impaired in most elderly individuals (Geffen et al., 1990; Mitrushina et al., 1991; Petersen et al., 1992; Knopman et al., 2003). Nonetheless, variability has been proposed to be increased with age, and life style and psychosocial factors to have influence on the heterogeneity of the older population and their aging process (Rowe and Kahn, 1987). While normal aging can be associated with a deterioration in different aspects of cognitive performance, the progression of mentioned phenomena could transform normal aging into dementia.

2.1.2. Definition of dementia

Dementia is a major public health problem, with no *mercie* for gender or for different ethnic and socioeconomic groups. Just as fever is attributed to many etiologies, dementia is a non-specific term that encompasses many disease entities. The word dementia is derived from latin *de-* "apart, away" and *mens* - on genitive, *mentis* "mind", so *de mens* - "without mind" and it is used scientifically for describing a progressive decline in cognitive function due to damage or disease in the brain, beyond what might be expected from normal aging. The term cognition comes from Latin as *cogito*, "to think" and it is used in several loosely-related ways to refer to a facility for the intelligent processing of information. In other words, dementia is a syndrome of brain dysfunction, with symptoms dependent upon the etiology of the disease. The affected areas may be memory, attention, language and problem solving, although particularly in the later stages of the condition, affected persons may be disoriented in time, place and identity.

There are different sets of criteria available for the diagnosis of dementia, as many authors and associations have tried to define it (American Psychiatric Association 1980 (DSM-III), 1987 (DSM-III-R) and 1994 (DSM-IV); Small et al., 1982; Cummings and Berson, 1983; McKhann et al., 1984; Dementia. Council on Scientific Affairs, 1986). The Diagnostic and Statistical Manual of Mental Disorders (DSM) of the American Psychiatric Association provides the most frequently used definition of dementia in the version III (DSM-III) (American Psychiatric Association, 1980), in the revised third version (DSM-III-R) (American Psychiatric Association, 1987), and in the version IV (DSM-IV) (American Psychiatric Association, 1994). The DSM-IV defines dementia as "the development of multiple cognitive deficits that include memory impairment and at least one of the following: aphasia, apraxia, agnosia, or a disturbance in executive functioning" (American Psychiatric Association, 1994.). The executive functioning is seen as the ability to inhibit inappropriate answers and to select behaviors for action. Thus, the memory impairment is necessary for defining this condition and the disturbances should interfere with the daily life. The cognitive impairment must be more pronounced than encountered in normal aging.

2.1.3. Alois Alzheimer and Alzheimer's disease

In medicine, eponymy has been traditionally used to memorialize the first diagnostician of a syndrome or a disease. That happened also with AD. Alois Alzheimer was born in June 14, 1864 in Marktbreit near Würzburg in Franconia, Germany. In 1888 he obtained his first post at the Mental Asylum, Irrenanstalt, in Frankfurt am Main, where later, the 51-year-old patient, Frau Auguste D was admitted, on November 25, 1901 and died on April 8, 1906. Alzheimer described her case of presenile dementia at the meeting of South-West Germany Psychiatrists in Tübingen, 1906 and published his presentation in 1907 (Alzheimer, 1907). While in life, the patient had shown a progressive decline in cognitive function, disorientation, aphasia, delusions, and psychosocial incompetence, at autopsy there were plaques and neurofibrillary tangles (NFT) and arteriosclerotic changes (Maurer et al., 1997). This was the original AD patient. As Bick KL remarked in the detailed historical description of Alzheimer's disease (Terry et al., 1999), "Alzheimer did not bestow his name on the condition he described", in fact Emil Kraepelin was the individual who introduced this disease as Alzheimer's disease in the category of presenile dementias in the 1910 edition of his textbook (Kraepelin, 1910). On the other hand, Alzheimer did not object to Kraepelin's designation, as he refers to it in his

publication (Alzheimer, 1911 - *English translation in Förstl and Levy, 1991*) on the report of a second patient with Alzheimer's disease, the case of 56-year-old male, Johann F. He states that Kraepelin has already given a summarized account on this disease and called it "Alzheimer's disease" (Möller and Graeber, 1998).

2.1.4. Diagnosis of AD

2.1.4.1. Clinically

Dementia has attracted extreme interest from public, clinicians and researchers, as the world population is aging. A major cause of dementia has been proposed to be AD, a progressive neurodegenerative disease, with a gradual onset varying between 40 and 90 of age and with a life span varying between 5 to 15 years after onset. The National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984) presented the most widely used criteria for clinical diagnosis of AD (Table1). The NINCDS-ADRDA criteria for clinical diagnosis of probable AD are equivalent with the criteria for defining the dementia of the Alzheimer type (DSM-IV) (American Psychiatric Association, 1994). Early diagnosis of AD is mainly based on clinical, neuropsychological, and brain imaging findings and exclusion of other possible causes for dementia, but no definite early tool for diagnosing the disease in point has been found until today. According to the NINCDS-ADRDA criteria, AD is divided into three categories: possible, probable and definite AD. The diagnosis of definite AD can be confirmed only by histopathological examination of the brain tissue obtained either by biopsy or at autopsy. Before that, a diagnosis of probable or possible AD has to be accepted (Table 1). Shortly, patients with probable AD are characterized by gradual onset and progression of memory and cognitive decline, and do not present any signs of other disorders that could cause dementia. The diagnosis of AD is supported by: progressive deterioration of specific cognitive functions such as language (aphasia), motor skills (apraxia), and perception (agnosia); impaired activities of daily living and altered patterns of behavior; family history of similar disorder, particularly if confirmed neuropathologically; normal cerebrospinal fluid (CSF) samples as evaluated by standard techniques; normal pattern or nonspecific changes in electroencephalography (EEG); and evidence of cerebral atrophy on brain imaging with progression documented by serial observation.

Table 1. The criteria for diagnosing AD according to the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA)

<p>Criteria for clinical diagnosis of PROBABLE Alzheimer's disease:</p> <ul style="list-style-type: none"> -dementia established by clinical examination and documented by objective testing; -deficits in two or more areas of cognition; -progressive worsening of memory and other cognitive functions; -no disturbance of consciousness; -onset between ages 40 and 90; -absence of systemic disorders or other brain diseases that in and of themselves could account for the progressive deficits in memory and cognition. <p>Criteria for clinical diagnosis of POSSIBLE Alzheimer's disease:</p> <ul style="list-style-type: none"> -may be made on the basis of the dementia syndrome, in the absence of other neurologic, psychiatric, or system disorders sufficient to cause dementia, and in the presence of variations in the onset, in the presentation, or in the clinical course; -may be made in the presence of a second systemic or brain disorder sufficient to produce dementia, which is not considered to be the cause of dementia; -should be used in research studies when a single, gradually progressive severe cognitive deficit is identified in the absence of other identifiable cause. <p>Criteria for diagnosis of DEFINITE Alzheimer's disease are:</p> <ul style="list-style-type: none"> -the clinical criteria for probable Alzheimer's disease; -histopathologic evidence obtained by biopsy or autopsy.
--

2.1.4.2. Neuropathologically

The neuropathological hallmarks of AD are amyloid plaques and neurofibrillary tangles (NFT) (Khachaturian, 1985; Braak and Braak, 1991 b; Mirra et al., 1991), but also other important signs are present: neuronal loss (Gomez-Isla et al., 1997) and synaptic loss (Hamos et al., 1989). The one neuropathological abnormality required for the definite diagnosis of AD is an adequate number of extracellular amyloid plaques (Khachaturian, 1985). This is according to the currently used neuropathological diagnostic criteria for AD, the Neuropathology Task Force of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (Mirra et al., 1991), a hallmark feature of the disease. The second neuropathological hallmark is the presence of neurofibrillary tangles (NFT) found inside the neurons, which form the basis of the Braak&Braak criteria with topographical staging (Braak and Braak, 1991 a; Braak and Braak, 1995). Accordingly, six stages of disease propagation can be distinguished with respect to the location of the NFTs: "transentorhinal stages I-II: clinically silent cases; limbic stages III-IV: incipient Alzheimer's disease; neocortical stages

V-VI: fully developed Alzheimer's disease" (Braak and Braak, 1995). Recently, a new set of criteria - based on both guidelines of CERAD and Braak&Braak criteria – was proposed by the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease (NIA) (NIA, 1997). The fact is that there are aged people free of any symptoms, and nevertheless on autopsy they present the neuropathological changes characteristic of AD. It was concluded in a recent review that disease-related pathological changes are the signs for an incipient disease like AD, rather than the effects of aging, even though there is a lack of clinical symptoms (Thal et al., 2004).

2.2. MCI

2.2.1. The concept of MCI


MCI is currently the most widely used concept in classifying cognitive impairment in the elderly who do not fulfil the criteria for dementia. Up to the present, a great interest was given to the changes responsible for cognitive impairment that are providing towards dementia, or to AD. For that, the boundary between normal aging and early AD has become the area of major interest for researchers and clinicians for theoretical and practical reasons (Petersen et al., 2001 a). Over the years, different concepts have been used to identify an intermediate stage of cognitive changes, for example: Benign senescent forgetfulness (Kral, 1962), Age-associated memory impairment (AAMI) (Crook et al., 1986), Age-associated cognitive decline (AACD) (Levy, 1994), Age-related cognitive decline (DSM-IV) (American Psychiatric Association, 1994), Mild cognitive disorder (ICD 10), Cognitive impairment - no dementia (Graham et al., 1997), Mild Cognitive Impairment (MCI) (Smith et al., 1996; Petersen et al., 1999). The concept of MCI has been the most recent research topic with still open questions on a large spectrum of issues involved in it (Petersen, 2003).

It should be noted that mildly impaired non-demented subjects form a heterogeneous group that includes stable subjects and subjects who will develop AD (Petersen, et al., 1995; Petersen, et al., 1999; Petersen et al., 2001 a), but also subjects that revert to normal aging (Larrieu et al., 2002). The heterogeneity (Figure 1) of the MCI group consisting of subjects declining to non-AD dementia, those progressing to AD, those that are stable and those that will revert to normal aging, may be viewed from two perspectives (Petersen, 2003): etiological or clinical presentation (Petersen et al., 1999). The most of decliners to AD are

those from the amnesic-MCI group of subjects, and they are characterized by impairment of the memory to 1.5 SD below age- and education matched normal subjects (Petersen et al., 1999). The memory impairment is a clinical judgment based on the subject's history, on the clinician's examination and on the neuropsychological profile, and it represents the main feature in the definition of MCI. Subsequently, memory impairment will remain the most important feature in diagnosing dementia, while other cognitive disturbances will interfere with the daily life (DSM-IV) (American Psychiatric Association, 1994).

In the Mayo Clinic, a progression rate of almost 12% per year was seen in declining from MCI to dementia or to probable AD, while the control cohort declined to MCI or to AD with a rate of only 2% per year (Petersen et al., 1999). The Report of the Quality Standards Subcommittee of the American Academy of Neurology reviewed in 2001 a number of studies and, even though these studies had used various criteria for MCI, they indicated an annual conversion rate of 6%–25% from MCI to AD (Petersen et al., 2001 a). Thus, investigating MCI might provide a means to study AD in its earliest phases and this might prove beneficial in terms of finding preventive or interventive measures for AD. However, some recent longitudinal population based studies have cast some doubt on the concept of MCI. Ritchie and colleagues suggested that MCI is a poor predictor of dementia, that the group is unstable, with cases changing category almost yearly, and they called for modifications to the current criteria (Ritchie et al., 2001). In the study by Larrieu et al. (2000), an annual conversion rate of 8.3% was observed during a five-year period, but again the cases had a tendency to fluctuate, and as many as 40% of MCI cases reverted to normal instead of progressing to dementia during the follow up. When considering the new recommendations for MCI criteria (Winbland et al., 2004), Alexopoulos and colleagues (2006 a) found that 17% of the MCI subjects returned to normal over a mean follow-up period of time of 3.5 years. The multiple-domain type of MCI had a less favorable prognosis than the amnesic type in progressing to dementia ($p < 0.014$) (Alexopoulos et al., 2006 b). Contrary, Yaffe and colleagues (2006) found that nonmemory and multiple-domain MCI subjects were less likely to progress to dementia than amnesic MCI subjects were, while among those that converted to AD, most had prior amnesic MCI.

Figure 1. The meaning of heterogeneity in MCI subjects. Both, the etiology of MCI and the clinical presentation will affect the heterogeneity of MCI group of subjects (adapted from the book edited by Petersen RC, 2003). Accordingly, MCI subjects will revert to normal, remain stable, or progress to AD or other dementias with time. The clinical presentation after Petersen et al.: Amnestic MCI – memory impaired to 1.5 SD below age- and education-matched normal subjects, while other domains are impaired to 0.5 SD; Multiple-domain MCI – several cognitive domains impaired to 0.5 SD below age- and education- matched normal subjects; Single non-memory-domain MCI – impairment is seen in other cognitive functions, for example in: executive function, visuospatial function, language.



In different studies, different criteria for defining MCI subjects have been used and the source of study differs, yielding different results. In some studies, the subjects are those who have actually sought an evaluation from a dementia clinic for different symptoms, and in others, they derive from community-based settings. Thus, differences exist in study designs, and ultimately the investigators need to interpret the results according to the limitations of their own study settings. Many ongoing studies continue to concentrate on MCI as a transitional stage between normal aging and AD or dementia.

2.2.2. Diagnosis of MCI

The criteria for MCI have been refined with time, but those used by many studies, including the current work, were based on the adaptation of the criteria suggested by Mayo Clinic Alzheimer's Disease Research Center (MCADRC) (Petersen et al., 1995; Smith et al., 1996):

- 1) memory complaint by patient, family or physician;
- 2) normal activities of daily living;
- 3) normal global cognitive function;
- 4) objective memory impairment or impairment in one other area of cognitive function as evidenced by scores >1.5 SD below age appropriate mean;
- 5) Clinical Dementia Rating score of 0.5; and
- 6) not demented.

Later those criteria were modified (Petersen et al., 1999):

- 1) memory complaint;
- 2) normal activities of daily living;
- 3) normal general cognitive function;
- 4) abnormal memory for age;
- 5) not demented.

A group of experts in aging and MCI (Petersen et al., 2001 b) and the subcommittee of the American Academy of Neurology (Petersen et al., 2001 a) have summarised the criteria for MCI, and placing the emphasis on the heterogeneity of this group of subjects, they defined 3 subgroups (Petersen et al., 2001 b): amnesic-, multiple domains slightly impaired- and single nonmemory domain MCI. Thus, MCI criteria became:

- 1) memory complaint, preferably corroborated by an informant
- 2) objective memory impairment
- 3) normal general cognitive function
- 4) intact activities of daily living
- 5) not demented.

Moreover, the amnesic MCI, considered as being the precursor for AD, is defined as:

- 1) memory complaint, preferably corroborated by an informant
- 2) impaired memory function for age and education
- 3) preserved general cognitive function
- 4) intact activities of daily living
- 5) not demented.

In 2003 during the First Key Symposium in Sweden, on the topic of MCI, an international multidisciplinary group of experts discussed the current status and new perspectives on clinical, cognitive neuroimaging, biomarkers and genetics fields in MCI. They gave recommendations for the general criteria for MCI, and published them in 2004 (Winblad et al., 2004):

- 1) Not normal, not demented (does not meet the DSM-IV, ICD 10 criteria for a dementia syndrome)
- 2) Cognitive decline:
 - self and /or informant report and impairment on objective cognitive tasks and/or
 - evidence of decline over time on objective cognitive tasks
- 3) Preserved basic activities of daily living/minimal impairment in complex instrumental functions.

This new set of criteria allows inclusion of deficits in cognitive domains other than memory, while the amnesic MCI would be then left as the precursor for AD, rather than for other dementias. Still, the clinical criteria as proposed by Petersen and colleagues, have varied from one study to another. Nevertheless, the criticisms raised against MCI criteria have not disappeared, and perhaps the criteria will be modified in the future. Recently, during a session of the MCI working group from the European Alzheimer's Disease Consortium (EADC), in 2005 a new set of criteria were presented for review (Portet et al., 2006):

- 1) cognitive complaint emanating from the patient and/or his/her family
- 2) the subject and/or informant report a decline in cognitive functioning relative to previous abilities during the past year
- 3) cognitive disorders evidenced by clinical evaluation: impairment in memory and/or another cognitive domain
- 4) cognitive impairment does not have major repercussions on daily life. However, the subject may report difficulties concerning complex day-to-day activities,
- 5) no dementia.

However, based on this report of the EADC, Portet and colleagues considered that in addition to those proposed criteria that would identify patients at risk to develop dementia, some more elaborate tests, like for example neuroimaging, will be still needed to determine the underlying cause of a diagnosed MCI state (Portet et al., 2006).

2.3. Imaging as an *in vivo* tool to study the brain

In studying the *normal state* of human brain and diagnosing cognitive pathology, MRI gained an important role as it provides qualitative and quantitative *in vivo* insights into brain morphology. New techniques are being developed continuously, and neuroimaging has become part of the diagnostic process of persons suspected for dementia. Quantitative structural studies are conducted both cross-sectionally and longitudinally and consist of volumetric measurements that focus on selected ROI, and computational methods that give insights into the global morphological changes in brain.

The goal for imaging studies is to achieve a consensus on applying imaging methods for early and differential correct diagnosis in dementia as a routine clinical procedure, as well as for monitoring the progress and outcome in drug trials. For that rationale, a "combination of a distinctive biochemical profile with quantitative neuroimaging, used in conjunction with clinical and neurobehavioral assessment" is urgently needed, as remarked by Black (1999) in what concerns the diagnosis of AD. According to the practice parameter on dementia (Knopman et al., 2001) the neuroimaging with MRI or computed tomographic (CT) plays a key role in the initial evaluation of a demented patient, as a means of ruling out structural lesions such as brain tumors, abscesses, strokes and hematomas. For this reason, the practice parameter supported the use of MRI or CT at the time of the initial dementia assessment. The Consensus Report of the Alzheimer's Association Neuroimaging Work Group recommended an extension of the guidelines of the American Academy of Neurology to include brain imaging as a part of the dementia evaluation in subjects when not only AD is suspected but also including amnesic MCI subjects (Neuroimaging Work Group, Alzheimer's Association. Consensus Report, 2004). The Work Group has recommended standardised analyses on the structural MRI, including the brain measurements of global loss and MTL volume, with the accent on longitudinal structural MRI study on brain atrophy rates that would provide information useful for the design of treatment studies (Neuroimaging Work Group, Alzheimer's Association. Consensus Report, 2004).

In what concerns the clinical practice, the visual rating method has high potential to be used in the clinical routine procedure for dementia investigations in the future. The visual rating method developed by Scheltens et al. (1992, 1995) has been applied to determine its value in differentiating AD patients from controls based on the MTL evaluation and has been

compared to that of a stereological volumetry method, a simplified version of manual tracing (Wahlund et al., 1999; Wahlund et al., 2000).

As for monitoring treatment effect in drug trials in AD promising results have been obtained by the boundary shift integral (BSI) method, an algorithm developed by Fox and colleagues (1996) and tested for brain (BBSI)-derived changes registered from serial MRI (Freeborough and Fox, 1997 and Fox and Freeborough, 1997). The BSI technique has been recently tested also for ventricular (VBSI)-changes and compared to BBSI changes in trials of a follow-up of 6 months and 1 year (Schott et al., 2005).

The BBSI and VBSI rates of change have been also compared to the ROI-based methods for ERC and hippocampus atrophy rates in classifying AD patients and controls (Ezekiel et al., 2004). While the rates of change were VBSI > ERC & hippocampus > BBSI in both groups, the combined rates of ERC and VBSI were the best explanatory variables for differentiation between the two groups of subjects. However, this study suggested that ERC and hippocampal atrophy rates might be more sensitive than BBSI or VBSI in monitoring the AD progression and the potential effects of disease modifying agents.

The neuroimaging methods and their efficacy differ according to the intention of use, such as clinical or research imaging tool, and the characteristics of those instruments with potential use in different clinical settings, are found in the consensus paper produced by the Neuroimaging Working Group of the European Alzheimer's Disease Consortium (EADC) (Frisoni et al., 2003).

The present work focuses on the most widely used neuroimaging tools for assessing the brain morphology, the manual tracing ROI-based MRI volumetry and the voxel-by-voxel method.

2.3.1. Imaging in normal aging brain - a view towards AD

2.3.1.1. Structural MRI and gray matter

Before one can define the *abnormal* there has to be a guideline for what is *normal*. Therefore, the imaging of the normal aging brain is an important issue, both for an *in vivo* regular anatomical presentation of the brain, and for the changes that are related to it.

Neuropathological studies have revealed changes in brain with advancing age. There is a constant hemisphere volume in individuals between the ages of 20 and 50 years (Miller et al., 1980), but thereafter there is a decrease in volume of 2% per decade (Miller et al., 1980; Jernigan et al., 1990).

Thus, after age of 50, the brain size suffers atrophy increased with age, but different studies have reported changes in brain connected with the process of maturation of brain during its life span: both global and selective decreases in cortical volume and an increase in ventricular volume have been detected in MRI studies. While Coffey and colleagues detected an age-associated decline in the volume of cerebrum both gray and white matter included (Coffey et al., 1992), Pfefferbaum and colleagues measured only the volume of cortical gray matter and found as well a linear decrease associated with age (Pfefferbaum et al., 1994). Different brain structures are involved in the process of age-related shrinkage and this is not uniformly distributed in the brain (Raz et al., 1997). Age related changes have been described in posterior frontal lobe with a decrease of about 1% per year, but not in temporal lobe in a group of subjects aged from 19-92 (DeCarli et al., 1994). Accordingly, Coffey and colleagues found in 76 subjects aged 30 to 90 years a frontal lobe volume reduction of 0.55% per year, but they also described a small decrease in temporal lobe (0.28% per year) (Coffey et al., 1992).

Regional brain volumes, such as those of hippocampus, parahippocampal gyrus and amygdala declined with increasing age according to some studies (Jack et al., 1997; Convit et al., 1995), while other studies detected no age effect on the hippocampal volume (Sullivan et al., 1995; Jack et al., 1989) or a very weak age effect (Raz et al., 1997). The "negative" results were obtained in studies including younger subjects, aged 21 to 70 years (Sullivan et al., 1995), or even 20 to 40 years (Jack et al., 1989). Thus, the results on age effect are somewhat contradictory but much of the variation is due to the different protocols used in choosing the study subjects as concerns age and number, or in measuring brain structures. For this same reason some workers have found a decline associated with age in hippocampal volume, but not in temporal lobe or the whole-brain (a study on 29 young adults) (Bhatia et al., 1993), while others found by contrast that left and right temporal lobe gray matter volumes, exclusive of the hippocampal measures, each decreased significantly with age (a study on 72 subjects aged 21 to 70 years) (Sullivan et al., 1995).

Brain changes rely mostly on cross-sectional studies. However, a better perspective on what may be the effect of age on brain's volume should be given by longitudinal studies. In a five-year study, Raz and colleagues reported an age-related shrinkage in the medial temporal lobe with a significant hippocampal decline, but minimal entorhinal changes (Raz et al., 2004). Later the longitudinal study by Raz and colleagues did detect age related shrinkage of the hippocampus and ERC, but accelerated shrinkage only in the hippocampus (Raz et al., 2005). These results are of particular importance when studying changes in brain related to dementia or AD.

2.3.1.2. A view towards AD

There is evidence that, although the hippocampus is affected early in the course of AD, the ERC is the first region to exhibit AD-type pathology (Van Hoesen and Hyman, 1990; Van Hoesen et al., 1991; Braak and Braak, 1991 a; Arriagada et al., 1992; Huesgen et al., 1993; Gomez-Isla et al., 1996). While in cognitively normal subjects (Clinical Dementia Rating (CDR) Scale = 0) the number of neurons in the ERC has remained constant between 60 and 90 years of age, even in the mildest form of dementia (CDR = 0.5) the number of neurons decreased by 32% (Gomez-Isla et al., 1996). Neurodegenerative changes in AD are accompanied by brain atrophy with changes generally seen in both gray and white matter (Mann, 1991). In layer II of the ERC, neuronal loss together with atrophy exists prior to the onset of dementia and is correlated with MMSE (Kordower et al., 2001), and hippocampal volumetry has been shown to correlate with neuronal (Bobinski et al., 2000) and tangle counts (Huesgen et al., 1993). Moreover, while MMSE and Braak&Braak stage are correlated, hippocampal volume measured on MRI scans correlates with each of them (Jack et al., 2002).

2.3.1.3. Structural MRI and white matter

Age-related white matter changes have been reported in some studies to appear between 30 to 79 years (Jernigan et al., 1991). Other studies reported that until 20 years of age, the cortical white matter volume increased steadily (subjects aged 3 months to 30 years), while after that age it remained constant (subjects aged 21 to 70 years) (Pfefferbaum et al., 1994). Coffey and colleagues reported a 6.3% per year increase in subcortical hyperintensity in the deep white matter in a sample of young healthy adults (Coffey et al., 1992). Age-related changes in white

matter have been presented also by Raz and colleagues, with no or very weak association with age (Raz et al., 1997).

2.3.1.4. VBM - gray and white matter

Apart of structural studies that concentrate on specific brain regions, of great importance are also other quantitative MR techniques that measure functional, blood-flow, biochemical or global anatomic changes occurring in the brain (Kantarci and Jack, 2004). One such approach is the voxel-based morphometric (VBM) method for studying the brain, which allows measurements of whole brain instead of a specific brain region. The voxel-by-voxel measurements indicate that prefrontal cortex and MTL are relevant structures both in aging and age-related cognitive decline in healthy elderly subjects (Tisserand et al., 2004). In the study by Good et al. (2001 a), a total of 465 normal adults were examined for age effects on gray and white matter. Accelerated volume loss with increasing age was seen in the insula, superior parietal gyri, central sulci and cingulate sulci, while little or no age effect was seen in the amygdala, hippocampus and ERC. Generally, a linear decline in gray matter was seen in normal aging, with sparing of the temporal lobe. White matter was in global terms not affected by age; nevertheless, local areas with age-related changes were seen.

2.3.2. Imaging in AD

Quantitative MRI measurements have been used to assess the volumetric AD changes in well-defined brain regions, selected according to the pathological changes known to occur in AD (Van Hoesen et al. 1991; Braak and Braak, 1991 a; Arriagada PV et al., 1992; Huesgen et al., 1993; Gomez-Isla et al., 1996). Neuroimaging, otherwise a part of the diagnostic workup of persons suspected for dementia, is even thought to be superior to the neuropsychological tests for early diagnosis of AD (Zamrini et al., 2004). A backup for studying certain ROIs are the reports of evidence that even cognitive intact subjects or MCI subjects can carry a burden of AD pathology (Huesgen et al., 1993; Bobinski et al., 2000; Jack et al., 2002). The MTL became therefore, an attractive target for MRI measurements. Structural brain studies are assessed with both ROI based measurements and global, computational based measurements, such as the VBM approach. In ROI measurements, the most consistent finding in AD has been hippocampal atrophy accompanied by ERC atrophy, and in general an atrophy of the MTL (see for review Dickerson and Sperling, 2005; Masdeu et al., 2005). Compared to

controls, the annual rate of hippocampal volume loss is two to three times greater in mild AD patients, ranging from 4-8% per year (Laakso et al., 2000; Jack et al., 2000). In cross-sectional studies, volume losses of 38% for the hippocampus (Laakso MP et al., 1995) and 40% for the ERC (Juottonen K et al., 1998 b) were registered in patients with mild to moderate AD versus controls. Accordingly, compared to MCI subjects, a volume loss of 19% for the hippocampus and 30% for the ERC has been reported (Du et al., 2001). While structures of the MTL, especially hippocampus and ERC, are considered MRI markers for AD, there are volumetric studies, which have focussed on other than temporal regions. Callen and colleagues studied the limbic system throughly: hippocampus, amygdala, parahippocampal cortex and "beyond the hippocampus", the anterior thalamus, hypothalamus, mamillary bodies, basal forebrain, septal area, fornix, and cingulate and orbitofrontal cortices (Callen et al., 2001). All the limbic structures exhibited significant atrophy, with the exception of one region: the anterior cingulate cortex.

The volumetric measurements were also studied from the discriminant point of view, since this has implications for the early diagnosis of AD (see for review Chetelat and Baron, 2003). Reviewing a good set of cross-sectional case-control studies, in 2004 Kantarci and Jack remarked that "the entorhinal cortex and hippocampus volumes are generally considered to be the most accurate in differentiating patients clinically diagnosed with AD from normal" (Kantarci and Jack, 2004). A combined atrophy of the limbic structures was used to distinguish patients with AD from controls with over 90% accuracy (Callen et al., 2001). Lehericy and colleagues (1994) achieved 100% accuracy in discriminating AD patients from controls combining the volume of hippocampus with that of amygdala; nonetheless, with hippocampus alone the accuracy achieved was only 89% (Lehericy et al., 1994). In addition, 100% accuracy in distinguishing mild AD patients from controls was achieved by combining partial ERC volume (measured from 3 slices) with measurements of the banks of the superior temporal and anterior cingulate sulci (Killiany et al., 2000). While some investigators have found almost no differences in the power of hippocampus and that of ERC for discrimination between AD patients and controls (Juottonen et al., 1999; Du et al., 2001), some others have reported a lower accuracy for the ERC (67%) than for the hippocampus (85%) for the same purpose (Frisoni et al., 1999).

More recent studies have paid attention on computational methods for analysing the atrophy throughout the brain, and in general if, focusing on VBM studies, they have confirmed

previous ROI-based findings that the brain atrophy is concentrated in the temporal lobe in AD (Ohnishi et al., 2001; Frisoni et al., 2002; Busatto et al., 2003). Yet, some investigators have found a widespread distribution of the atrophy (Baron et al., 2001; Karas et al., 2003). This raises questions about what is happening globally in brain morphology in patients at high risk for dementia, moreover for AD.

2.3.3. Imaging in MCI

In recent years, subjects at high risk for developing dementia, or more exactly AD, have been intensively studied using *in vivo* neuroimaging methods, though the results must be interpreted with caution taking into account the set of subjects studied and the appropriate way of defining them. Even if we concentrate only on MCI subjects, we meet different categories of criteria used for collecting the study group, which can influence the results obtained in different studies. Furthermore, the neuroimaging protocols employed differ from one study to another as well. This thesis will focus rather on ROI-based measurements and VBM analyses on brain to review some basic findings in this field.

2.3.3.1. MRI volumetric studies in MCI

Due to the reduced volumes detected by MRI in AD, the ERC and hippocampus have consequently been the regions of major interest in MCI. Thus, most of the MRI studies in MCI have been dedicated to ROI measurements. An extensive review on neuroimaging in MCI stated that the decline in volumes reported in different studies ranged from 13% to 32% in the ERC and from 9% to 15% in hippocampus (Wolf et al., 2003) in MCI subjects versus controls. Nonetheless, the MCI subjects were chosen based on different criteria in the various studies as were the protocols used for measurements of ERC. Therefore, a straight comparison between studies is difficult to make. However, the ERC and hippocampal volumes are significantly reduced in those subjects determined to be at a transitional stage between normal aging and dementia, when compared with controls (Convit et al., 1997; Dickerson et al., 2001; Xu et al., 2000; Du et al., 2001). Yet, some investigators reported more atrophy in the ERC than in hippocampus (Xu et al., 2000), while others found no differences in the magnitude of the volume loss between these two regions (13% versus 11%) in MCI versus controls (Du et al., 2001). Convit and colleagues (1997) described a hippocampal volume reduction of 14% between subjects with minimal cognitive impairment,

termed as MCI and controls. In that study, the MCI subjects were defined according to Global Deterioration Scale (GDR) = 3, not using the MCADRC criteria for MCI (Petersen et al. 1995; Petersen et al., 1999) and there were no reports on the ERC volume.

For defining the boundaries of the ERC, researchers have used different protocols, like that by Insausti et al. (1998) in studies by Du et al. (2001) and Xu et al. (2000), but also that by Goncharova et al. (2001). With this latter protocol, Dickerson and colleagues (2000) studied ERC and hippocampus in subjects "who presented at the clinic with cognitive complaints, but did not meet criteria for dementia (non-demented)". As this was a longitudinal study, they found that the converters were differentiated from non-converters only by the ERC volume, suggesting that the ERC atrophy appears before that of the hippocampus and thus, it is a better predictor of conversion. Moreover, the non-demented subjects were better distinguished from controls with the ERC volume (69% accuracy) than with the hippocampal volume. Xu et al. (2000) reported a more powerful overall classification with the hippocampal volume than with the ERC volume, between MCI subjects and controls, while Killiany et al. showed that only the ERC volume could discriminate normals from "questionables" (83% accuracy) and from converters (84% accuracy) (Killiany et al., 2002). "Questionables" were defined using a clinical dementia rating of 0.5 and not the MCADRC criteria for MCI (Petersen et al., 1995; Petersen et al., 1999) and the ERC volume in this study was measured from only 3 slices of 1.5mm each. "Questionables" and converters could not be discriminated with any of these two regions. In another study by Killiany et al. (2000) the best discrimination between the groups of normal subjects and "questionables" or converters was achieved with the ERC, the banks of the superior temporal sulcus, and the anterior cingulate (accuracy 85%, respectively 93%). In that study, no data on the hippocampal atrophy has been reported.

Apart of the two above discussed MRI markers for AD, other regions started more recently to gain interest in neuroimaging. The cingulate cortex is part of the limbic system, involved in memory functions, and here a severe hypometabolism of glucose rate has been found, especially in the hippocampal complex, medial thalamus, mamillary bodies, and posterior cingulate, in patients with MCI and mild AD (Nestor et al., 2003). Yet, this is a study using a combination between the techniques of MRI with that of positron emission tomography (PET). A ROI study reporting the cingulate atrophy in preclinical AD is for instance that of Killiany et al. (2000).

Results presented by the studies searching for brain atrophy with ROI are in a way limited to the fact that, not all of them included subjects defined as MCI according to the probably most largely used criteria of MCADRC for MCI (Petersen et al., 1995; Petersen et al., 1999); furthermore, the number of subjects was small as for such a heterogenic group; the neuroimaging protocols are not constant throughout the studies; and one should beforehand plan what brain region to study, thus, significant atrophy may exist and not be detected in other regions. For the last inconvenience more recent studies on MCI have employed rather semi-, or automatic methods, for example the voxel-by-voxel measurements for detecting global brain atrophy.

2.3.3.2. VBM studies in MCI

There are only a few studies employing VBM analysis in MCI (Chetelat et al., 2002; Karas et al., 2004; Chetelat et al., 2005; Bell-McGinty et al., 2005), while before the VBM work included in this thesis was started there was only one published study on this topic (Chetelat et al., 2002). That study applied VBM on 22 patients with amnesic MCI compared to 22 controls and reported significant gray matter (GM) loss in the hippocampal region, and the cingulate gyri, with extension into the temporal neocortex. Bell-McGinty's study had an interesting design, presenting not only the GM atrophy in MCI subjects versus controls, but also morphologic changes in subgroups of MCI: amnesic group and group with more diffuse cognitive impairment (Bell-McGinty et al., 2005). Atrophy in the hippocampus and ERC, and in the amygdala and the neocortex was found in the amnesic MCI group of subjects when compared to controls.

A recent study reported significant atrophy in global GM of 12.3% in AD compared to controls, while the GM atrophy in the MCI group was not significantly different from either controls (6.5%) or AD group (6.2%) (Karas et al., 2004). Still, they found a spatial difference between the study groups. The atrophy of the MTL, thalamus and insula were significant for the MCI group versus that of controls, while the GM atrophy in the parietal association cortices and in the cingulate cortex was found in AD versus MCI. Nevertheless, while very early thalamic atrophy is not specific for Braak&Braak staging for AD, a glucose hypometabolism has been reported to appear early also in this region (Nestor et al., 2003). The thalamic involvement in MCI has been shown with VBM analysis (Chetelat et al.2005; Chen and Herskovits, 2006). As the VBM can estimate a global GM loss, annual rates ranging

from 0% to 4% have been reported during 18 months of follow-up of 18 MCI subjects, with the highest rates present in frontal temporal and cingulate cortices in converters, and in frontal areas in non-converters (Chetelat et al., 2005). The same group of researchers found an annual GM loss of ~4% in the temporal neocortex, 1-2% in the hippocampus and 3-4% in the ERC in converters. GM loss has been intensively studied in AD and MCI with ROI and VBM, but it seems that this is not the only morphological change in the brain associated with dementia.

2.3.4. WMLs and associations with MCI

There is evidence that the prevalence of white matter lesions (WMLs), defined by volume, distribution or substrate increases with age, and while the elevated blood pressure is considered to be the strongest predictor of WML, there are also other disease conditions and evermore, genetic factors that may contribute to the presence of WMLs (see for review Launer, 2003). Moreover, in 51 healthy subjects aged 19 to 91 years without cerebrovascular risk factors, the white matter hyperintensity volume was predictive of reduced cognitive scores, reduced brain volume and increased ventricular volume (DeCarli et al., 1995). The above-mentioned study considered the white matter hyperintensity volume to be abnormal if it represented more than 0.5% of the intracranial volume. In a very recent study on dementia- and stroke-free subjects, the so called large white matter hyperintensity volume was significantly associated with decreased cognitive functioning dependent rather on the frontal lobe systems, but also on the medial temporal area, though to a lesser extent (Au et al., 2006). Yet, associations between the memory impairment and WMLs remain uncertain, based on a study of 40 normal subjects (O'Brien et al., 1997). In a MCI study, apart of APOE ϵ 4 and age, the white matter hyperintensity volume was also associated with increased risk for MCI, even when excluding subjects who had suffered cerebrovascular accidents (DeCarli et al, 2001). Wolf and colleagues (2000) found an inverse relationship between WMLs and the temporal lobe atrophy in the group of MCI subjects that progressed to dementia during a follow-up period of 2-3 years. It has been suggested that WMLs could accelerate the cognitive decline in MCI subjects and contribute to the dementia process (Wolf et al., 2000), though a more recent longitudinal study reported that WMLs did not predict decline (Korf et al., 2004). Thus, there is a need of including the WML burden into both cross-sectional and longitudinal studies on MCI to try to achieve a consensus on whether and to what degree those changes contribute to the development of dementia in subjects with MCI.

2.3.5. MRI volumetry - a predictor of AD in MCI

An annual conversion rate of 6-25% from MCI to AD has been reported, regardless of the MCI criteria used in different studies (see for review Petersen et al., 2001 a). For the conversion to dementia, respectively to AD in MCI studies different parameters have been used: APOE genotype, neuroimaging and neuropsychological batteries, as being *in vivo* predictive markers for AD. The visual assessment of the MTL atrophy was shown to predict dementia in MCI subjects independently of age, gender, education, MMSE, CDR sum of boxes score, APOE ϵ 4, and WML burden (Korf et al., 2004). Important MCI longitudinal study designs are both finding predictors to dementia/AD and comparing groups of converters with nonconverters as concerns different features. In terms of MTL atrophy and hippocampal atrophy significant differences between MCI converters and nonconverters were reported, with increased atrophy being seen in decliners (Erten-Lyons et al., 2006). That study did not provide data about the entorhinal cortex volume. In a recent longitudinal study with a follow-up of 5 years, the most important MRI markers for AD, being ERC and hippocampus, were examined as predictors for AD, but only the ERC volume and its rate of decline was found to be an independent predictor of AD, not the hippocampal volume (Stoub et al., 2005). The MCI subjects they studied had been diagnosed according to the Mayo Clinic criteria for amnesic MCI (Petersen et al., 1999), and the volumetric MRI protocol used for the ERC volume was that developed by Goncharova and colleagues (Goncharova et al., 2001). The data reported were obtained from 58 nondemented elderly participants including both amnesic MCI subjects and healthy controls with no cognitive impairment, all studied as one group. In a review on predictors of conversion to dementia, Modrego suggested that a combination of a neuroradiological technique, APOE genotype and cognitive tests may be the best option for prediction purposes, until a 100% marker will be detected. Moreover, he considered that the ERC and hippocampal atrophy markers are problematic because of anatomic variations and artefact possibilities (Modrego, 2006).

2.4. APOE and implications in MCI and AD

2.4.1. What is APOE?

ApoE is a plasma lipoprotein involved in lipid transport and metabolism, which is synthesized and secreted by many tissues, primarily liver, but also by brain, as well as by skin and tissue

macrophages throughout the body (Saunders et al., 2000). The polymorphism of the human APOE gene, located on chromosome 19, consists on 3 different alleles: $\epsilon 2$, $\epsilon 3$ and $\epsilon 4$, with the APOE $\epsilon 3$ being the most common in the general population (77%-78%), while APOE $\epsilon 2$ represents only 7%-8% and APOE $\epsilon 4$ 14%-15% (Cedazo-Miguez and Cowburn, 2001). It is known that the human ApoE is a 299 amino acid apolipoprotein, where the three isoforms (ApoE2, E3 and E4) differ from one another due to the amino acid changes in positions 112 and 158. ApoE3 has cysteine at residue 112 and arginine at residue 158, E2 has cysteine at residue 112 and 158 and E4 has arginine at residue 112 and 158. The amino acid changes in these positions lead to different lipid binding properties and they are responsible for the association of each of the isoforms with different diseases (Mahley and Rall, 2000; Cedazo-Miguez and Cowburn, 2001).

2.4.2. APOE and implications in AD

The presence of the APOE allele $\epsilon 4$ has been the most consistently confirmed genetic risk factor for AD (Farrer et al., 1997). In a meta analysis, it was shown that the effect of APOE as a major risk factor for AD was seen both in men and women, in all ages between 40 and 90 years, though the risk effect diminished after the age 70 years (Farrer et al., 1997). Some studies have also suggested that AD patients carrying APOE $\epsilon 4$ have more pronounced neuropathological changes, exhibit more prominent atrophy of the MTL, and suffer more severe memory loss compared to AD patients with no $\epsilon 4$ allele (Lehtovirta et al., 1995; Petersen et al., 1995; Alberts, 1996; Lehtovirta et al., 2000; Engelborghs et al., 2003).

Regarding the atrophy of MTL regions in AD, a dose-dependent effect of the APOE $\epsilon 4$ allele was shown using ROI-based methods, where atrophy increased significantly from non-carriers to homozygous carriers via heterozygous carriers (Lehtovirta et al., 1996; Juottonen et al., 1998 a; Geroldi et al., 1999). In a study by Boccardi et al. (2004) using VBM analysis, some of the MTL regions (amygdala and right hippocampal tail) were atrophied in AD carriers of APOE $\epsilon 4$ versus AD non-carriers. Again, using volumetric measurements, Lehtovirta and colleagues (1995) showed that amygdaloid damage was greater in AD patients homozygous for the $\epsilon 4$ allele, than in heterozygous or noncarriers.

The presence of APOE $\epsilon 4$ has shown a significant role in predicting conversion from MCI to AD (Petersen et al., 1995; Alberts, 1996; Kryscio et al., 2006), though there are also data

reporting negative results on the predictive value of APOE $\epsilon 4$ for conversion from MCI to AD (Korf et al., 2004; Wang et al., 2006). Korf and colleagues presented data showing that visual assessment of MTL structures on MRI using a standardized rating scale is a predictor of dementia in MCI subjects independently of age, gender, education, MMSE, CDR sum of boxes, APOE genotype, and WML burden, while APOE did not predict conversion to dementia (Korf et al., 2004).

2.4.3. APOE and implications in MCI

The presence of APOE $\epsilon 4$, as mentioned above, is strongly implicated in the conversion from MCI to AD, although there are contradictory results on this topic, but even more, it increases the risk of MCI (DeCarli et al., 2001; Lopez et al., 2003; Tervo et al., 2004; Kryscio et al., 2006). Recently, Fleisher and colleagues found that MCI women carriers of one or two APOE $\epsilon 4$ allele have more reduced hippocampal volume than controls, and that this situation in MCI men was repeated only for carriers of APOE $\epsilon 4/\epsilon 4$ (Fleisher et al., 2005). Earlier, Farlow and colleagues reported that the APOE $\epsilon 4$ genotype in MCI subjects was associated with greater impairment in memory and functional activities, and a greater decline in the hippocampal volume, results that resemble those obtained in AD patients (Farlow et al., 2004). Contradictory, Killiany and colleagues found no significant difference in the volume of the ERC or the hippocampus in relation to APOE genotype; moreover, the APOE status did not add power on the discrimination between groups of controls, questionables, converters and AD patients (Killiany et al., 2002).

Of interest is the finding from a longitudinal study of a total of 129 subjects followed-up for 3 ± 1 years, where the proportion of individuals with APOE $\epsilon 4$ increased in the following order of clinical outcome: control-stable (10%) < control-decliner (20%) < MCI-stable (28%) < MCI-decliner (39%) < AD (46%) (Jack et al., 2000). However, there are conflicting results in the literature about APOE and its effect on brain morphology in MCI subjects and on the conversion from normal to MCI and to AD. Moreover, little is known about the global effect of APOE on the brain, especially on the GM.

3. AIMS OF THE STUDY

The focus of this thesis was to concentrate on MCI subjects in the Kuopio MCI study applying the hypotheses: those who later convert to AD have lower memory test scores, more hippocampal and ERC atrophy and more often have APOE ϵ 4 allele, compared to controls and stable MCI subjects. Additionally, MCI carriers of APOE ϵ 4 allele have more profound atrophy of the brain than noncarriers, and higher risk to convert to dementia.

The specific aims of studies **I-IV** were:

1. To determine whether the ERC atrophy precedes hippocampal atrophy in AD, and to evaluate the power of discrimination between the diagnostic groups using MRI volumetry (**study I**).
2. To map the GM loss in the entire brain of MCI patients using VBM method (**study II**).
3. To investigate the difference in the morphologic expression of MCI in subjects carriers and noncarriers of the ApoE ϵ 4 allele using the VBM method (**study III**).
4. To conduct a follow-up study and to determine what is the predictive value of the MRI-derived volumes of the hippocampus and ERC, WML, APOE, age, gender, education, MMSE and CDR sum of boxes on conversion from MCI into AD (**study IV**).

4. SUBJECTS AND METHODS

4.1. Subjects

The study was approved by the local ethics committee, and all the participants gave informed consent for their participation in the study. The original set of the studied subjects was 172, including 59 controls, 65 MCI subjects and 48 subjects with AD. The MCI and control subjects were derived from two population-based cohorts in whom cognitive functions of the elderly had been evaluated (Hänninen et al., 2002 and Kivipelto et al., 2001). AD patients were selected from hospital series and were investigated in the Department of Neurology, Kuopio University Hospital, Kuopio, Finland. **Study I** was a volumetric study that used ROI-based measurements and included the entire set of 172 subjects: 59 controls, 65 MCI subjects and 48 subjects with AD. **Study II** and **III** used VBM method for inspecting the brain atrophy and included 32 controls and 51 MCI subjects, for whom technically adequate scanning parameters were available for the VBM method. **Study III** was designed to assess the brain atrophy in MCI subjects related to their APOE genotype. The individuals with MCI were divided into three subgroups according to their APOE status: 28 were $\epsilon 4$ noncarriers, 15 were heterozygous for the $\epsilon 4$ allele, and 8 were homozygous for the $\epsilon 4$ allele. **Study IV** included 60 subjects with MCI for whom clinical follow-up data and brain volumetry data was available. The baseline visit included the brain MRI scan in addition to clinical and neuropsychological evaluation. There were no reasons for excluding subjects from the study on the basis of vascular pathology based on T2 weighted images. Three follow-up visits were performed in 1999-2004, and they included neuropsychological tests and clinical neurological examination. Finally, the medical history (hospital records) was obtained for those participants who did not participate in all study visits to detect the possible conversion to dementia. The conversion to dementia was considered as the end-point of the follow-up.

4.1.1. Control subjects

Control subjects were volunteers from the population-based cohorts. They had neither dementia nor MCI and were matched by age and gender with the MCI/demented subjects. The methods used for the identification of control subjects have been published earlier in detail (Hänninen et al., 1997 and Kivipelto et al., 2001). The controls showed no impairment in the cognitive tests, and had no history of neurological or psychiatric diseases.

4.1.2. AD subjects

The subjects with AD were derived from hospital series of well characterized AD patients investigated in the Department of Neurology, Kuopio University Hospital, Kuopio, Finland. The diagnostic evaluations for AD patients included medical history, physical and neurological examinations performed by a physician, and a detailed neuropsychological evaluation administered by a neuropsychologist. The severity of cognitive decline was graded according to the CDR Scale (Berg, 1988). Furthermore, brain MRI scan, CSF analysis, ECG, chest radiography and blood tests were performed. These were not used in the diagnostic phase except for excluding other possible pathologies underlying the symptoms. The diagnosis of dementia was based on the criteria of the DSM-IV (American Psychiatric Association, 1994) and the diagnosis of AD on the NINCDS-ADRDA criteria (McKhann et al., 1984).

4.1.3. MCI subjects

The subjects with MCI were identified from two different population cohorts. In both cohorts, the evaluation consisted of a structured interview including the CDR Scale and an extensive neuropsychological assessment. The scoring of the CDR was independent of the scores obtained from neuropsychological tests. MCI was diagnosed using the criteria proposed by Mayo Clinic Alzheimer's Disease Research Center. Later, these criteria have been modified, but at the time this study was conducted the criteria required: (1) memory complaint by patient, family, or physician; (2) normal activities of daily living; (3) normal global cognitive function; (4) objective impairment in memory or in one other area of cognitive function as evident by scores >1.5 S.D. below the age-appropriate mean; (5) CDR score of 0.5; and (6) absence of dementia (Petersen et al., 1995 and Smith et al., 1996).

In the first cohort, the following test battery was used for a comprehensive neuropsychological evaluation of different cognitive domains: *Memory*: Visual Reproduction Test (immediate and delayed recall) from Wechsler Memory Scale (Russel, 1975), Logical Memory Test (immediate and delayed recall) from Wechsler Memory Scale-Revised (Wechsler, 1987), Word List Recall (immediate and delayed recall) from the CERAD Neuropsychological Assessment Battery (Morris et al., 1989), delayed recall of the Constructional Praxis from CERAD (Morris et al., 1989), New York University Paragraph

Recall (immediate and delayed recall) (Kluger et al., 1999); *Language*: Abbreviated (15 items) Boston Naming Test (Kaplan et al., 1991), vocabulary subtest from the Wechsler Adult Intelligence Scale-Revised (WAIS-R) (Wechsler, 1981); *Attention and executive function*: Verbal Fluency Test (Borkowski et al., 1967 and Butters et al., 1987), Trail Making Test (Reitan, 1958) parts A and B; *Visuospatial skills*: Constructional Praxis from CERAD, Block Design from the WAIS-R (Wechsler, 1981); *Global functioning*: Mini-Mental State Examination (Folstein et al., 1975) (MMSE), Clock Drawing Test (the CERAD version) (Morris et al., 1989). In this cohort, however, two memory test scores only were used as the objective psychometric criteria of memory impairment in MCI diagnosis: according to the normative data (Hänninen et al., 2002) in delayed recall in the Logical Memory Test from the WMS-R or in the Visual Reproduction Test from the WMS, he or she was defined as impaired. All the MCI subjects included in the present study had memory impairment.

The diagnostic procedure used in the second cohort has been previously described in detail (Kivipelto et al., 2001). The cognitive functions were screened using the MMSE. Subjects scoring < 24 in the MMSE were invited to participate in the clinical phase to assess the possibility of MCI. Ultimately, 86% subjects took part in the clinical phase, which consisted of taking of medical history, thorough neurologic and cardiovascular examinations performed by a physician, and a detailed neuropsychological evaluation conducted by a neuropsychologist that included the Buschke Selective Reminding Test (Buschke and Fuld, 1974), the Logical Memory Test from the Wechsler Memory Scale-Revised (Wechsler, 1987), the Boston Naming Test (Kaplan et al., 1983), the Vocabulary subtest of the WAIS-R (Wechsler, 1981), the Verbal Fluency Test (Borkowski et al., 1967), the Copy a Cube Test (Goodglass and Kaplan, 1972), the Clock Setting Test (Goodglass and Kaplan, 1972), the Block Design subtest of the Wechsler Adult Intelligence Scale (Wechsler, 1981 b), the Wisconsin Card Sorting Test using Nelson's version (Nelson, 1976), and the Trail Making Test (Reitan, 1958). The severity of cognitive decline was graded by the study physician according to the CDR scale. A review board consisting of the study physician, the study neuropsychologist, and a senior neurologist ascertained the preliminary diagnosis based on all available information. As defined by the MCADRC criteria, the cut-off point 1.5 SD below the norm in the neuropsychological tests was used as a guideline in the clinical assessment of cognitive performance. Thus, both psychometric and clinical aspects were taken into account in the ultimate diagnosis of MCI as suggested by the MCADRC criteria. All the MCI subjects included in the present study had memory impairment.

4.2. Imaging of the brain

4.2.1. MRI and volumetric studies

4.2.1.1. MRI technique for volumetric study

The subjects were scanned with a 1.5 T Siemens scanner (Siemens Magnetom SP or Vision, Erlangen, Germany) using a three-dimensional magnetization prepared rapid acquisition gradient echo sequence (For the 13 controls and 30 AD patients scanned before year 1998: time of repetition (TR) 10 ms, time of echo (TE) 4 ms, matrix 256×256, 1 acquisition and in plane resolution=0.98 mm; For 32 controls, 4 AD patients and 51 MCI subjects scanned in 1998/1999: TR=9.7, TE=4, matrix 256×256, 1 acquisition and in plane resolution=0.98 mm; For 14 MCI subjects scanned in 1999/2000/2001: TR=13.5, TE=7, matrix 256×256, 1 acquisition and in plane resolution=0.94 mm) resulting in contiguous T1-weighted partitions with a slice thickness of 1.5-2.0 mm oriented perpendicular to the long axis of the hippocampus. The images were then aligned to correct for the undesirable effects of head tilt and rotation. Standard neuroanatomical landmarks (such as the orbits, sulci and the commissures) were used to correct for possible deviations in any of the orthogonal planes and the scans were reconstructed into 2.0 mm thick contiguous coronal slices, oriented perpendicular to the intercommissural line. T2 weighted images were also acquired, and used to study the possibility of vascular pathology in the cases.

4.2.1.2. Determination of volumes

The hippocampi and ERCs (Figure 2) were manually traced (Figure 3) by a single tracer (C.P.), blinded to the clinical data, using custom-made software for a standard Siemens work console. The boundaries of the ROI were outlined by a trackball driven cursor and number of voxels within the region was calculated by using the in-house developed program for standard work console. Thus, once the ROI had been traced, the software calculates the volume for every structure by computing the number of voxels for each traced image. The outlining of the boundaries always proceeded from anterior to posterior. Data from a standard anatomical atlas of the human brain (Duvernoy, 1999), and from previous articles were used as guidelines

to determine the boundaries of the hippocampus (Laakso et al., 1998) and the ERC (Insausti et al., 1998).

Figure 2. Hippocampus and ERC in controls, MCI, mild AD and moderate AD





Figure 3. ROI-volumetry of the left ERC and right hippocampus



4.2.1.3. Measurement of the hippocampal volume

Tracing of the hippocampus started rostrally where the hippocampus first appears below the amygdala and ended posteriorly in the section where the crura of the fornices depart from the lateral wall of the lateral ventricles. The hippocampus included the dentate gyrus, the hippocampus proper and the subicular complex.

4.2.1.4. Measurement of the ERC

The ERC volumes were traced according to the histology-based criteria designed for MRI volumetric measurements (Insausti et al., 1998). In brief, the most anterior slice measured was the one after the appearance of the temporal stem, and the last slice was the one where the uncus and gyrus intralimbicus were no longer separable.

4.2.1.5. Measurement of the ICA

The coronal intracranial area (ICA) was measured at the level of the anterior commissure and it was used for normalization of the volumetric data. For the purpose of data presentations, the volumes were normalized to the intracranial area according to the formula:

$(\text{volume/intracranial area}) \times 100$.

4.2.1.6. Validation studies

The intraclass correlation coefficients for intrarater reliability were 0.96 for the hippocampus and 0.95 for the ERC measured from 10 subjects.

4.2.2. VBM


In the VBM method, the brains of groups of subjects are modified in a pre-processing phase, in order to fit a reference template, such that a stereotactic point refers to the same structure in each normalized brain. Then automatic statistical analyses are carried out, that compare the concentration of gray matter in each voxel.

4.2.2.1. VBM pre-processing

After removing the voxels below the cerebellum with MRIcro software (www.psychology.nottingham.ac.uk/staff/cr1/mricro.html) (Rorden and Brett, 2001) the MR images were analysed with Statistical Parametric Mapping (SPM99) (www.fil.ion.ucl.ac.uk/spm) running under Matlab 5.3 (Mathworks, Sherborn, MA, USA).

The MR images were pre-processed following a protocol, which included (1) generation of a *customised template*, (2) generation of *customised prior probability maps*, and (3) the *main VBM steps* (Figure 4): *normalisation* of the original MR images, *segmentation* of normalised images, cleaning of grey matter images, modulation of grey matter images, and *smoothing* of modulated images.

Figure 4. Main VBM steps, after LENITEM.



The advantages of this procedure over the traditional simple protocol are that (1) the use of template and prior probability maps computed from the population under study reduces the error in the normalisation and segmentation steps, (2) the cleaning step permits removal of non-brain voxels erroneously classified as grey matter (Good et al., 2002), and (3) modulation permits preservation of the original volume of grey matter within each voxel (Ashburner and Friston, 2000; Ashburner and Friston, 2001; Good et al., 2001 b).

(1) Customised template

The customised template was obtained by normalising the images of the 51 MCI patients and 32 controls to the Montreal Neurological Institute template (Evans et al., 1994) of SPM99 using a 12 parameter affine transformation, smoothing the normalised images with an 8 mm isotropic Gaussian kernel and averaging the smoothed images. The anterior commissure was manually set as the origin of the spatial coordinates and images were reoriented coronally perpendicular to the intercommissural line. The normalisation procedure uses a bilinear interpolation algorithm to reslice images to a voxel size of 2x2x2 mm. This voxel size was used in the following processing and analysis.

(2) Customised prior probability maps

Customised prior probability maps were computed by segmenting the normalised images into GM, white matter (WM), and CSF, then smoothing with an 8 mm Gaussian filter, and finally averaging the segmented images, thus obtaining the customised prior probability maps specific for GM, WM, and CSF (Good et al., 2002). The voxels, which probability of being brain was greater than 0.5 were smoothed with an 8-mm isotropic Gaussian kernel in order to create the customized brain mask.

(3) Main VBM steps

Original images were *normalised* to the customised template through affine and non-linear transformations, medium regularisation, reslicing 2x2x2 mm, and no masking (Baron et al., 2001). The normalised images were *segmented* into GM, WM, and CSF using the customised prior probability maps. The *Xbrain* routine, based on erosions and dilatations, was used to remove voxels of non-brain tissue from the segmented images, thus obtaining a brain mask to clean the GM images by intersection with the mask. In the modulation step, voxel values of the cleaned GM images were multiplied by the measure of relative volumes of warped and unwarped structures derived from the non-linear step of spatial normalisation (Jacobian determinant) (Good et al., 2002). The modulated GM images were *smoothed* with a 12 mm isotropic Gaussian kernel. The final output is a 3D matrix where the three indices are the spatial x, y, and z coordinates of voxels in the reference space, and each value of the matrix is proportional to the volume of GM within each voxel. It should be emphasised that the output of each stage of the analysis was visually checked to ensure that the algorithms had actually carried out the expected changes.

4.2.3. Determination of WMLs

The WMLs were evaluated by a single rater (R.R.) on MRI images on a computer screen with either proton density (PD) and T2 weighted images or on T2 or FLAIR images by using the rating scale by Wahlund et al. (2001). The WMLs were defined as bright lesions ≥ 5 mm on T2, PD or FLAIR images. In frontal, temporal, parieto-occipital, and infratentorial regions, WMLs were scored: 0 = no lesions (including symmetrical, well-defined caps or bands), 1 = focal lesions, 2 = beginning of confluence of lesions, 3 = diffuse involvement of the entire region; and in the basal ganglia: 0 = no lesions, 1 = one focal lesion (≥ 5 mm), 2 = more than one focal lesion, 3 = confluent lesions. The sum score of frontal, temporal, parieto-occipital, basal ganglia, and infratentorial regions were used in the analysis.

4.3. Determination of APOE genotype

APOE genotype was determined from blood leukocytes. DNA was extracted by a standard phenol-chloroform extraction, and APOE genotypes were analyzed by polymerase chain reaction and HhaI digestion as described previously (Tsukamoto et al., 1993).

4.4. Statistical analyses

4.4.1. MRI volumetric analyses

Study I

The statistical software SPSS for Windows V10.0 (SPSS Inc., Chicago, IL) was used to analyze the data. In all statistical analyses of the volumetric data, volumes normalized for the intracranial area were used. One-way ANOVA with Bonferroni post hoc analysis was used to compare the means of age, education, and MMSE scores between the groups. The relationship of volumes with gender, diagnostic groups and age was assessed with the ANCOVA test, which had hippocampal and ERC volumes as dependent variables, gender and diagnostic groups as factors, and age as covariate. Pearson's correlation coefficients were used to analyze the correlation between the hippocampal and ERC volumes within each study group. We tested the value of the hippocampal and ERC volumes in discriminating between the groups using discriminant analyses with enter and stepwise methods, respectively. In the analyses, the normalized volumes to the intracranial area and adjusted for age were used.

First, discriminant analyses with an enter method were used to analyze the value of normalized total volumes of the hippocampus and ERC to distinguish AD patients or MCI subjects from controls and MCI subjects from patients with AD, using volumes as independent variables. Then, the value of the hippocampal and ERC total volumes for group classification were tested using stepwise discriminant function analyses (Wilks' method). Finally, stepwise discriminant analysis was used to test unilateral volumes: the right and left hippocampal volume, the right and left ERC volume in discrimination between pairwise combinations of clinical groups. The results are expressed as mean±S.D. The level of statistical significance of differences is $P<0.05$. The discrimination between groups was also represented with ROC curves.

Study IV

The statistical software SPSS for Windows V11.5 (SPSS Inc., Chicago, IL) was used to analyze the data. In all statistical analyses of the volumetric data, we used volumes normalized for the intracranial area. Student's T test was used to assess group differences. The effect of side (within group variable) and outcome (between-group variable) on the volumes of the hippocampus and ERC was assessed by ANOVA. Interaction terms were included in the model as needed. Because of the variability in the follow-up length, the predictive accuracy of volumetry for dementia was assessed by Cox's regression analysis with follow up time as the time variable and conversion to dementia or AD as the status variable. The hazard ratios (HR) with 95% CI and significance (p value) are presented. The level of statistical significance of differences was set at $p<0.05$.

4.4.2. VBM analyses

Study II

A "Single subject: Conditions and Covariates" model was used to compare the volume of GM between MCI and controls on a voxel by voxel basis. The analysis was controlled for APOE genotype including genotype ($\epsilon 3/3$, $\epsilon 3/4$, and $\epsilon 4/4$) as a dummy variable. Intracranial area, age, and sex were included as nuisance covariates. The resulting t map was thresholded at $p<0.001$, uncorrected. The demographic and clinical data were analysed using one way ANOVA or χ^2 test, the level of significance was set at $p<0.05$.

Study III

The individuals with MCI were divided into three subgroups according to their APOE status: 28 were $\epsilon 4$ noncarriers, 15 were heterozygous for the $\epsilon 4$ allele, and 8 were homozygous for the $\epsilon 4$ allele. The "Single subjects – Conditions and Covariates" procedure was used to compare the gray matter volume between MCI and controls and between MCI carrying and not carrying the $\epsilon 4$ allele. Intracranial area, age and sex were included as nuisance covariates. The regions atrophic in individuals heterozygous and homozygous for the APOE $\epsilon 4$ allele were detected by contrasting all MCI subjects to controls and inclusively masking atrophy of individuals heterozygous and homozygous for the APOE $\epsilon 4$ allele relative to noncarriers. This approach allows detecting areas of atrophy of noncarriers related to both heterozygous and homozygous carriers of the $\epsilon 4$ allele. The resulting t map was thresholded at $p < 0.001$, uncorrected.

5. RESULTS

5.1. Descriptive characteristics

The groups from **study I** were well matched for age ($F=1.5$, $P=0.24$) and gender ($\chi^2=2.4$, $p=0.30$). The MMSE scores declined in the following order: control>MCI>AD ($p<0.001$) (Table 1). The level of education differed significantly across the study groups ($F[2,164]=4.3$, $p<0.05$); the subjects with MCI had significantly a lower level of education compared to controls (Bonferroni post hoc analysis $P<0.05$).

In **study II** there was no difference in age ($F = 1.96$, $p = 0.17$), sex ($\chi^2 = 0.45$, $p = 0.50$), education ($F = 0.20$, $p = 0.66$), or frequency of the APOE $\epsilon 4$ allele ($\chi^2 = 2.5$, $p = 0.11$) between the controls and cases with MCI. As expected, the Mini-Mental State Examination scores were significantly lower in cases with MCI compared with the controls ($F = 24.8$, $p<0.0001$) (Table 2).

In **study III** the groups of MCI individuals according to the APOE polymorphism were also matched for age, gender and MMSE (Table 2).

For the subjects from **study IV**, the mean follow-up time was 34 (SD 8.7, range 10 to 54) months. During this period, 13 (21.7 %) patients had progressed to dementia (progressive MCI). Nine (69%) patients in this group had a clinical diagnosis of probable AD, three had vascular dementia and one had dementia of mixed type. In the stable MCI group, seven subjects had a neuropsychological profile of control subjects in the last follow-up visit. At baseline, there were no differences between the outcome groups in education, age, MMSE score (Table 2), follow-up time [months as mean (SD): 35.2(8.2) for the stable MCI group versus 30.7(9.9) for the progressive MCI group], or in the WML load [mean (SD): 4.2(4.5) in the stable MCI group versus 4.5(2.9) in the progressive MCI group]. Patients with stable MCI had lower ($p<0.05$) CDR sum of boxes [1.2(0.5), for subjects $n=45$] compared to patients with progressive MCI [2.1(1.1), for subjects $n=12$]. The progressive MCI group included eight patients with at least one APOE $\epsilon 4$ allele. Three patients were heterozygous for the APOE ϵ allele ($\epsilon 3/\epsilon 4$) and five were homozygous ($\epsilon 4/\epsilon 4$). Five patients with the progressive MCI were $\epsilon 4$ non-carriers ($\epsilon 3/\epsilon 3$). The stable MCI group consisted of 21 APOE $\epsilon 4$ allele carriers. Eighteen of them were heterozygous for the APOE $\epsilon 4$ allele (17 $\epsilon 3/\epsilon 4$, 1 $\epsilon 2/\epsilon 4$), and three

were homozygous. Twenty-six subjects in the stable MCI group were $\epsilon 4$ non-carriers (25 $\epsilon 3/\epsilon 3$, 1 $\epsilon 2/\epsilon 3$). The APOE groups (at least one $\epsilon 4$ allele, no $\epsilon 4$ allele) did not differ in age, education, follow-up time, baseline MMSE score, or CDR sum of boxes in progressive MCI. In subjects with stable MCI the only statistically significant difference was found in the follow-up time as subjects without the APOE $\epsilon 4$ allele had a longer follow-up time compared to subjects with $\epsilon 4$ allele (mean \pm SD: 37.9 ± 5.46 versus 31.7 ± 9.79 , $p < 0.05$).

Table 2. Descriptive characteristics

Study	CONTROLS		MCI						AD
	I	II&III	I	II&III			IV		I
				ϵ -/-	$\epsilon 4$ -	$\epsilon 4/4$	stable	progressive	
Number	59	32	65	28	15	8	47	13	48
Age	73(4)	74(4)	73(5)	72(5)			73(4)	72(4)	71(8)
				73(4)	71(5)	70(3)			
Sex	37(63)	19(59)	43(66)	17(61)	13(87)	4(50)	33(70)	8(62)	25(52)
Education	8(3)	7(2)	7(2)	7(2)			7(2)	7(2)	7(3)
MMSE	27(2)	27(2)	24(3)	24(2)			24(3)	23(2)	21(4)
				24(4)	24(3)	23(2)			
ApoE $\epsilon 4$ +/-	13/45	9/22	30/35	23/28			21/26	8/5	32/16

MCI: mild cognitive impairment; AD: Alzheimer's disease; MMSE: Mini-Mental State Examination; Sex: female (%); Age, Education and MMSE expressed as mean (SD); ApoE $\epsilon 4$ +/-: carriers of at least one ApoE $\epsilon 4$ allele / noncarriers. For one control subject, the ApoE genotype is not known.

5.2. MRI volumetry of hippocampus and ERC in controls, AD subjects and MCI subjects (study I)

The objective in this study was to determine the volumetric differences for the hippocampus and the ERC between the study groups of controls, MCI and AD. Moreover, we intended to determine the power in discrimination between the study groups for unilateral and total volumes of hippocampus and ERC.

5.2.1. Comparative volumetric measurements in controls, AD subjects and MCI subjects

The diagnostic groups (controls, MCI and AD) differed significantly in the volumes ($F[2,164]=88.2$, $p<0.001$ for hippocampal volume; $F[2,164]=50.1$, $p<0.001$ for ERC volume), gender had no influence on the volumes ($F[1,164]=1.1$ for hippocampal volume,

$F[1,164]=0.03$ for ERC volume, $p>0.05$), gender \times group had no influence on the volumes ($F[2,164]=0.2$ for hippocampus, $F[2,164]=2.3$ for ERC volume, $p>0.05$), and age did not affect the hippocampal volume ($F[1,164]=2.6$, $p>0.05$), but it did affect the ERC volume ($F[1,164]=8.2$, $p=0.01$). While age was not correlated with total ERC volume in the control group ($r=-0.23$, $p=0.09$) or in the MCI group ($r=-0.15$, $p=0.22$), in the group of patients with AD there was a significant correlation between age and the total ERC volume ($r=-0.30$, $p=0.04$). Therefore, all the analyses were adjusted for age.

The total hippocampal volume and the total ERC volume, as well as the unilateral volumes of hippocampus and ERC were significantly reduced in the following order: control>MCI>AD (Table 3). The total hippocampal and total ERC volumes were correlated within each group (control: $r=0.35$, $p=0.01$; MCI: $r=0.53$, $p<0.001$; AD: $r=0.58$, $p<0.001$).

Table 3. Volumetric measurements and percentual decrease in volume

Region	Controls	MCI		AD	
	Volume	Volume	Decrease (%)	Volume	Decrease (%)
Hippocampus					
Right	16.37 \pm 2.19	15.20 \pm 2.51*	7	10.55 \pm 2.86§‡	36
Left	15.36 \pm 2.23	13.90 \pm 2.54†	10	9.34 \pm 2.48§‡	39
Total	31.73 \pm 4.19	29.10 \pm 4.77†	8	19.90 \pm 5.10§‡	37
Entorhinal cortex					
Right	9.02 \pm 1.89	7.65 \pm 1.59†	15	5.88 \pm 1.92§‡	35
Left	8.47 \pm 1.94	7.00 \pm 1.50†	17	5.29 \pm 1.62§‡	38
Total	17.49 \pm 3.63	14.66 \pm 2.96†	16	11.18 \pm 3.20§‡	36

The analyses represent normalized volumes. The results are expressed as mean \pm S.D. and the decrease % is compared with controls. Right: right side; Left: left side; Total: sum of the right plus left side volumes; MCI: mild cognitive impairment; AD: Alzheimer's disease.

* $p < 0.05$ for MCI vs. controls


§ $p < 0.001$ for AD vs. MCI

‡ $p < 0.001$ for AD vs. controls

† $p < 0.001$ for MCI vs. controls

The percentual decrease in ERC volume was higher compared to that in the hippocampal volume in the MCI group versus controls, whereas the volume losses in the AD group versus controls were of the same magnitude for the hippocampus and ERC (Figure 5).

Figure 5. The percentual decrease of total ERC and total hippocampal (HC) volumes within each study group relative to mean volumes for the control group. The 95% CI is considered.



5.2.2. Discriminant function analyses

In discriminant function analysis, we used first the enter method for the volumes of the total (right and left) hippocampus and total (right and left) ERC, adjusted for age and thereafter a stepwise method to test the accuracy of first total and thereafter unilateral volumes in classifying the groups (Table 4).

In the classification between MCI subjects and controls, the volume of the total hippocampus yielded an overall classification of 59.7% (Wilks' $\lambda=0.92$, $\chi^2=10.1$, $p=0.01$), the volume of the total ERC yielded an overall classification of 66.7% (Wilks' $\lambda=0.84$, $\chi^2=21.3$, $p<0.001$). In the stepwise analysis, only the total ERC volume entered the model with an overall classification of 65.9% (Wilks' $\lambda=0.84$, $\chi^2=21.0$, $p<0.001$). In the stepwise discriminant function analysis including unilateral hippocampal and ERC volumes only left ERC volume entered the model (Wilks' $\lambda=0.85$, $\chi^2=20.3$, $p<0.001$) (Table 4).

Distinguishing AD patients from control subjects, the volume of total hippocampus yielded an overall classification of 90.7% (Wilks' $\lambda=0.36$, $\chi^2=105.1$, $p<0.001$), the total ERC volume yielded an overall classification of 82.1% (Wilks' $\lambda=0.50$, $\chi^2=70.8$, $p<0.001$). In the stepwise analysis both the hippocampal volume and the ERC volume entered the model (overall classification 90.6%, sensitivity 87.6%, specificity 93.1%; Wilks' $\lambda=0.34$; $\chi^2=111.1$; $p<0.001$). In the stepwise discriminant function analysis including unilateral hippocampal and ERC volumes, the left hippocampal volume and the right ERC volume entered the model (Wilks' $\lambda=0.35$, $\chi^2=108.1$, $p<0.001$) (Table 4).

Table 4. Classification between the groups using discriminant function analysis with the enter method including in the model hippocampus (HC), or entorhinal cortex (ERC), as well as with the stepwise method including in the model both the HC and ERC

Groups and variables	Sensitivity %	Specificity %	Overall classification %	P
MCI and Controls				
Enter: HC	56.9	62.7	59.7	0.01
Enter: ERC	63.1	70.7	66.7	<0.001
Stepwise: ERC	66.2	65.5	65.9	<0.001
AD and Controls				
Enter: HC	85.4	94.9	90.7	<0.001
Enter: ERC	85.4	79.3	82.1	<0.001
Stepwise: HC + ERC	87.6	93.1	90.6	<0.001
AD and MCI				
Enter: HC	77.1	83.1	80.5	<0.001
Enter: ERC	70.8	70.8	70.8	<0.001
Stepwise: HC	81.3	83.1	82.3	<0.001


The analyses included the bilaterally summed and normalized volumes adjusted for age. MCI: mild cognitive impairment; AD: Alzheimer's disease.

Distinguishing AD patients from MCI subjects, the total hippocampal volume showed an overall classification of 80.5% (Wilks' $\lambda=0.52$, $\chi^2=72.0$, $p<0.001$), the ERC volume yielded an overall classification of 70.8% (Wilks' $\lambda=0.73$, $\chi^2=34.1$, $p<0.001$). In the stepwise analysis, only hippocampal volume entered the model (overall classification 82.3%, sensitivity 81.3%, specificity 83.1%; Wilks' $\lambda=0.53$, $\chi^2=69.3$, $p<0.001$). In the stepwise discriminant function analysis including unilateral hippocampal and ERC volumes, only left hippocampal volume entered the model (Wilks' $\lambda=0.55$, $\chi^2=66.0$, $p<0.001$) (Table 4).


ROC curves were used to illustrate the discrimination between groups with hippocampal and ERC volumes (Figure 6).

Figure 6. ROC curves representing discriminations between groups with MRI volumetry: a). control-MCI; b). control-AD; c). MCI-AD


a).



b).



c).



5.3. VBM analyses in MCI subjects (study II)

The objective of this study was, using APOE genotype as a confounding factor, to determine the pattern of brain atrophy in MCI subjects.


MCI subjects exhibited the greatest atrophy in the right hippocampus-amygdala region, and in the right hippocampal tail and thalamus, when compared to controls (Figure 7, Table 5). The medial temporal structures on the left did not quite achieve the level of statistical significance. Other regions with significant gray matter atrophy were detected in the right superior temporal gyrus, the left thalamus, the left inferior temporal gyrus, and the left anterior cingulate gyrus (Table 5).

Table 5. Atrophic regions of MCI cases compared with controls ($p < 0.001$, uncorrected)

Cluster size k	Region	Stereotactic coordinates (mm)			Z score
		x	y	z	
147	Right thalamus	12	-14	12	3.74
	Right hippocampus (tail)	24	-34	4	3.42
	Right thalamus	16	-26	0	3.31
246	Right amygdala-hippocampus	24	-4	-16	3.72
14	Left superior parietal lobule	-16	-60	66	3.36
10	Right superior temporal gyrus	56	8	-6	3.31
6	Left thalamus	-8	-14	12	3.27
15	Left anterior cingulate gyrus	-10	2	42	3.24
2	Left inferior temporal gyrus	-66	-20	-28	3.16
10	Left thalamus	-16	-30	8	3.14

Region denotes the areas of maximal grey matter volume loss within each cluster. For example: the first line denotes the presence of a 3D cluster created from 147 contiguous voxels of significantly decreased ($p < 0.001$) gray matter volume. Within the same cluster, there are two more peaks of significance more than 8 mm from the former and located at 24, -34, 4 and at 16, -26, 0. The most significant voxel of the cluster has stereotactic coordinates of 12, -14, and 12 and is located in the region of the right thalamus.

Figure 7. Medial temporal involvement in MCI patients compared with controls with $p < 0.001$, uncorrected. Significant voxels are superimposed on MR images of a single control subject. Atrophy affects the amygdala and the head and tail of the hippocampus.




5.4. VBM analyses in MCI subjects, carriers of APOE $\epsilon 4$ (study III)

The objective of this study was to determine first the pattern of brain atrophy in MCI subjects with no APOE confounding used, thereafter to map the gray matter loss in MCI subjects carriers of APOE $\epsilon 4$.

MCI subjects exhibited the greatest atrophy in the right and left amygdala, right parahippocampal gyrus, left medial dorsal thalamic nucleus and right superior temporal gyrus, when compared to controls (Figure 8, Table 6).

Figure 8. Regions of atrophy in MCI. **a** Atrophy in 15 MCI with one $\epsilon 4$ allele compared to 28 MCI without APOE $\epsilon 4$. **b** Atrophy in 8 MCI with 2 $\epsilon 4$ alleles compared to 28 MCI without APOE $\epsilon 4$.



In the comparison between MCI individuals heterozygous for the APOE $\epsilon 4$ allele and noncarriers only the right parahippocampal gyrus, with the ERC included, reached the level of statistical significance (Figure 8 a, Table 6). The most significant atrophy between homozygous for the $\epsilon 4$ allele and noncarriers was located in the right amygdala followed by the right parahippocampal gyrus, the left amygdala and the left medial dorsal thalamic nucleus (Figure 8 b, Table 6).

When compared to controls, APOE ϵ 4 noncarriers showed the widest and most significant clusters of atrophy in the parahippocampal gyrus bilaterally (on the right: cluster size 102 voxels, coordinates 24, -36, 2, $z = 3.73$; on the left : cluster size 34 voxels, coordinates -22, -4, 14, $z = 3.31$) and in the left medial dorsal thalamic nucleus (cluster size 24 voxels, coordinates -6, -14, -12, $z = 3.43$). Other smaller clusters were located in the temporoparietal regions bilaterally.

Table 6. Atrophic regions of MCI subjects compared to controls ($p < 0.001$ uncorrected) and of MCI subjects in study groups subdivided according to the APOE genotype

Cluster size k	Region	Stereotactic coordinates (mm)			Z score
		x	y	z	
MCI versus controls					
326	Right amygdala	26	-6	18	3.81
152	Right parahippocampal gyrus	24	-36	2	3.73
24	Left medial dorsal thalamic nucleus	-6	-14	12	3.43
53	Left amygdala	-22	-4	-14	3.31
3	Right superior temporal gyrus	56	8	-6	3.17
MCI ϵ 4+/- versus MCI ϵ 4-/-					
1	Right parahippocampal gyrus	18	-40	6	3.10
MCI ϵ 4 ++ versus MCI ϵ 4 -/-					
326	Right amygdala	26	-6	-18	3.81
133	Right parahippocampal gyrus	24	-36	2	3.73
52	Left amygdala	-22	-4	-14	3.31
2	Left medial dorsal thalamic nucleus	-6	-16	8	3.18
1	Left medial dorsal thalamic nucleus	-4	-14	10	3.14

Cluster size is given in number of voxels. Region denotes the areas of maximal grey matter volume loss within each cluster. For example, the first line denotes the presence of a 3D cluster created from 326 contiguous voxels of significantly decreased ($p < 0.001$) gray matter volume, with stereotactic coordinates of 26, -6, 18 and located in the right amygdala.

5.5. Predictors of AD in MCI subjects (study IV)

The aim of this study was to determine the hippocampal and ERC volume loss in those MCI subjects that progressed to dementia, or to AD during a period of mean follow-up time of 34 months, a group so called "progressive MCI" compared to those MCI subjects that did not convert to dementia, so called "stable MCI". One additional objective of this longitudinal study was to determine the predictive value of the MRI-derived volumes of MTL structures, WML, severity of cognitive impairment, and APOE genotype on conversion of MCI to dementia and AD.

5.5.1. Volumetric measurements at baseline

At baseline, patients with progression of MCI to dementia had significantly reduced ($p < 0.01$) volume of the right hippocampus and the right ERC (Table 7) versus patients with stable MCI. A similar trend was found in the analysis of the volumes of the left hippocampus and the left ERC, but this difference did not reach statistical significance. However, the total volume (sum of the right and left side) of the hippocampi and the ERCs were significantly reduced ($p < 0.05$) in the progressive MCI group vs. stable MCI group (Table 7). The lowest volumes were found in patients with progression of MCI to AD (right hippocampus: 12.9 ± 2.4 , left hippocampus: 12.2 ± 2.7 , right ERC: 6.1 ± 1.3 , left ERC: 5.8 ± 0.6), and all of the analyzed volumes were significantly reduced ($p < 0.05$) compared to the stable MCI group.

In the progressive MCI group there was a tendency of decreased volumes in those patients with at least one APOE $\epsilon 4$ allele, and the volumes of the left hippocampus and the total volume of the hippocampi reached statistical significance ($p < 0.05$) (Table 7, Figure 9). In the group of stable MCI, there were no significant differences in the volumes of hippocampi or ERCs in the APOE groups.

In the progressive MCI group, patients with at least one $\epsilon 4$ allele had significantly reduced total volumes in hippocampus and ERC as well as lowered volumes of the right and the left side separately ($p < 0.05$) compared to subjects with stable MCI with at least one $\epsilon 4$ allele (Table 7, Figure 9). On the other hand, there were no differences in these volumes between the stable or progressive MCI groups in the subjects without the APOE $\epsilon 4$ allele (Figure 9).


Table 7. Volumes of hippocampus and ERC

	Stable MCI	Progressive MCI
Right HC	15.52 (2.36)	13.53 (2.26) #
APOE ϵ 4+	14.99 (2.48)	12.75 (2.38)
APOE ϵ 4-	15.96 (2.20)	14.79 (1.51)
Left HC	14.19 (2.25)	12.80 (2.68)
APOE ϵ 4+	13.96 (2.02)	11.26 (2.03)
APOE ϵ 4-	14.38 (2.43)	15.27 (1.42)
Total HC	29.71 (4.42)	26.33 (4.54)*
APOE ϵ 4+	28.94 (4.39)	24.01 (3.83)
APOE ϵ 4-	30.34 (4.42)	30.06 (2.81)
Right ERC	7.91 (1.56)	6.62 (1.44) #
APOE ϵ 4+	7.96 (1.73)	6.11 (0.95)
APOE ϵ 4-	7.87 (1.44)	7.42 (1.82)
Left ERC	7.11 (1.53)	6.44 (1.45)
APOE ϵ 4+	7.22 (1.37)	5.88 (0.75)
APOE ϵ 4-	7.02 (1.68)	7.34 (1.91)
Total ERC	15.02 (2.98)	13.06 (2.74)*
APOE ϵ 4+	15.17 (3.00)	12.00 (1.59)
APOE ϵ 4-	14.90 (3.02)	14.76 (3.50)

Results are mean (SD). HC: normalized volume of the hippocampus; ERC: normalized volume of the entorhinal cortex; Total: sum of the right plus left side volumes; APOE ϵ 4+/ ϵ 4- : at least one APOE ϵ 4 allele/ no APOE ϵ 4 allele.

* $p < 0.05$; # $p < 0.01$

Figure 9. Total volumes of the hippocampus and entorhinal cortex (EC) in stable and progressive MCI in subjects with at least one APOE $\epsilon 4$ allele or without any $\epsilon 4$ allele. Filled circles represent patients with conversion of MCI to AD during the follow-up period.



5.5.2. Predictors for conversion to dementia

In the univariate Cox's regression analysis, the volumes of the hippocampus and ERC on the right side, the total volume of the hippocampi, and the CDR sum of boxes significantly predicted the progression of MCI to dementia (Table 8). The baseline MMSE score, WML burden, or the APOE $\epsilon 4$ allele were not significant predictors of progression. When patients with non-AD dementia were excluded, the right, left and total hippocampal and ERC volumes significantly predicted the progression to AD (Table 8). In this analysis CDR sum of boxes, MMSE scores, WML burden or APOE $\epsilon 4$ allele were not significant predictors for AD.

Table 8. Cox's univariate regression analysis with follow-up (months) as time variable and outcome (Dementia, AD) as status variable

	Dementia	AD
Right HC	0.738 (0.58 - 0,94) *	0.668 (0.49 - 0.91) #
Left HC	0.866 (0.68 - 1.10)	0.739 (0.55 - 1.00) **
Total HC	0.881 (0.77 - 1.00) **	0.815 (0.69 - 0.97) *
Right ERC	0.597 (0.38 - 0.93)*	0.439 (0.25 - 0.77)#
Left ERC	0.836 (0.56 - 1.24)	0.568 (0.34 - 0.95)*
Total ERC	0.824 (0.65 - 1.04)	0.651 (0.47 - 0.90)#
Age	0.991 (0.87 - 1.12)	0.972 (0.84 - 1.12)
Gender	0.625 (0.20 - 1.98)	0.543 (0.15 - 2.04)
MMSE at baseline	0.919 (0.73 - 1.16)	0.918 (0.70 - 1.20)
CDR sum of boxes	2.730 (1.55 - 4.81)###	1.948 (0.90 - 4.21)
Education	0.979 (0.68 - 1.42)	1.198 (0.78 - 1.84)
APOE ε4 allele	0.534 (0.17 - 1.69)	0.359 (0.89 - 1.44)
WML load	1.007 (0.89 - 1.14)	1.016 (0.88 - 1.17)

Results are expressed as Hazard Ratio (95 % confidence interval). HC: normalized volume of the hippocampus; ERC: normalized volume of the entorhinal cortex; total: sum of the right plus left side volumes; AD: conversion of MCI to Alzheimer's disease; MMSE: Mini-Mental State Examination; CDR: Clinical Dementia Rating Scale; WML: white matter lesions.

* p < 0.05

** p = 0.05

p < 0.01

p < 0.001

In bivariate Cox's regression analysis, the CDR sum of boxes and the volumes of the right ERC remained significantly associated with progression of MCI to dementia, whereas progression of MCI to AD was significantly associated only with the baseline volumes of the ERCs (Table 9).

Table 9. Cox's bivariate regression analysis with follow-up (months) as the time variable and outcome (Dementia, AD) as the status variable

	Dementia	AD
Right HC	0.805 (0.61 - 1.07)	0.731 (0.52 - 1.03)
CDR sum of boxes	2.627 (1.43 - 4.84) [#]	1.685 (0.71 - 4.00)
Left HC	0.952 (0.73 - 1.24)	0.812 (0.59 - 1.11)
CDR sum of boxes	2.721 (1.53 - 4.83) ^{##}	1.829 (0.80 - 4.17)
Total HC	0.932 (0.81 - 1.07)	0.864 (0.72 - 1.03)
CDR sum of boxes	2.675 (1.48 - 4.84) ^{##}	1.723 (0.73 - 4.05)
Right ERC	0.577 (0.35 - 0.94) [*]	0.448 (0.24 - 0.83) [#]
CDR sum of boxes	3.124 (1.67 - 5.86) ^{##}	2.222 (0.93 - 5.33)
Left ERC	0.787 (0.50 - 1.24)	0.542 (0.30 - 0.97) [*]
CDR sum of boxes	3.001 (1.60 - 5.64) ^{##}	2.268 (0.93 - 5.50)
Total ERC	0.799 (0.62 - 1.02)	0.658 (0.47 - 0.92) [*]
CDR sum of boxes	3.175 (1.67 - 6.05) ^{##}	2.285 (0.93 - 5.60)

Results are expressed as Hazard Ratio (95 % confidence interval). HC: normalized volume of the hippocampus; ERC: normalized volume of the entorhinal cortex; total: sum of the right plus left side volumes; AD: conversion of MCI to Alzheimer's disease; CDR: Clinical Dementia Rating Scale.

* p < 0.05

p < 0.01

p < 0.001

6. DISCUSSION

6.1. Study subjects

The MCI and control subjects studied in this work have been collected from two large population-based cohorts. This is of importance when interpreting the results from a brain MRI study-design that concentrates on MCI, compared to studies where subjects are collected from a memory clinic. Noteworthy is also the careful clinical evaluation and diagnosis applied in the Kuopio cohorts. The criteria set used for MCI diagnosis (Petersen et al., 1995; Smith et al., 1996) represent that most widely used at the time when MCI patients started to be collected in our research center. From the two Kuopio cohorts, a database was compiled suitable for the objectives and aims of this work, resulting in a large and representative group of subjects (n=65 MCIs and n=59 controls), for whom the brain MRI scans were evaluated. Thus, this is a relatively large MR imaging study with a well documented MCI population.

Limitations of such a long-term imaging-study are the changes and updates in scanning parameters and protocols. This had implications on the number of subjects included in the VBM-based study (n=51 MCIs and n=32 controls). In addition, a further limitation is the small number of subjects homozygous for APOE ϵ 4 allele, especially when studying the differences between and within the groups of stable MCI and progressive MCI (n=3, respectively n=5), but this is the case for our study-population in the way the APOE alleles are distributed.

6.2. MRI techniques

The ROI-based volumetry is a basic method to investigate atrophy in the brain, though limited to the region planned to be studied, and it could be easy to apply also in the clinical work, provided that the tracer would have enough experience in performing the task. Nevertheless, the time needed to accomplish such a task may still be of inconvenience for a clinical purpose. A visual rating method is certainly much quicker, with a time required of 1-2 minutes per subject (Wahlund et al., 2000), and for that reason it is more convenient for use as a routine diagnostic tool in future dementia investigations. The VBM method is a more advanced method intended to investigate atrophy taking a global view of the brain, but it is not possible to apply it as a diagnostic tool in routine clinical work. However, VBM method is

a very useful research tool. It provides an *in vivo* insight into morphological changes in the brain at the group level, but it requires a set of normative images taken with the same scanner. Nevertheless, the purpose of this study was not to determine what would be the best imaging method for detecting atrophy in brain during clinical work, but this could be one point for future study.

A strong point of this work is that with only ROI-based method this imaging study is an *in vivo* evidence supporting the Braak&Braak statement (Braak and Braak, 1991 a; Braak et al., 1993), showing that entorhinal atrophy precedes the atrophy in the hippocampus in MCI, whereas hippocampal atrophy is more prominent in AD. Additionally, the present imaging study could map the atrophy that occurs in the brain during a preclinical AD phase, the MCI stage, moreover taking into account the influence of APOE genotype, a well known risk factor for AD (Farrer et al., 1997). The novelty of this work, compared to previous research done in MCI subjects, is that we examined the effects of the APOE $\epsilon 4$ allele on brain morphometry in MCI using the VBM method.

Although there are other good predictors for AD, the ERC and hippocampal volumes were the only features to predict conversion to AD from the MCI stage, which had been diagnosed according to the Mayo Clinic criteria (Petersen et al., 1995; Smith et al., 1996). When using VBM, other regions were also shown to be implicated in MCI, but are there other and/or better predictors of dementia/AD than the ERC and hippocampal volumes, it is not shown in this work. This is an objective for a future study for the Kuopio cohorts, when applying for that purpose an automatic imaging method to map the entire brain, with VBM or other new imaging techniques. If VBM analyses are to be conducted, then newer software than the SPM99 (www.fil.ion.ucl.ac.uk/spm) could be used, and that would allow more accurate image processing. However, that would make it more difficult to compare the results even within the same research group. There are divergences already when trying to compare the findings using ROI and VBM (Good et al., 2002, Tisserand et al., 2002 and Karas et al., 2003). For example, in **study I** the percentage volume loss in MCI relative to controls was greater on the left hippocampus and ERC, while in **study II** the predominant unilateral atrophy was on the right side. This may be accounted for the different amount of subjects included in the two studies, **study II** having a reduced amount of both, MCI and control subjects, or for the differences in the applied two MRI techniques to study the brain: manual and automatic estimations, or for both of the reasons. The VBM method also entails some

limitations and possible confounders that may have importance on the results. For example, the quality of the scans given by the reduction of gray/white matter contrast in the diseased people and the greater frequency of motion effects in this group may be of importance. Moreover, the registration errors of regional specificity that may appear with the spatial normalisation, especially of small structures, such as hippocampus or ERC are, may be more variable in a diseased group, which might reduce the sensitivity of VBM to detect changes, that otherwise would have higher intensity on manual measurements. Another inconvenience when trying to compare studies is the statistical p value used for analysis when applying VBM, some using $p < 0.001$ value uncorrected, while others have the p corrected for multiple comparisons. For a very heterogeneous group such as MCI, a $p < 0.001$ value uncorrected may be a better choice, while from the statistical point of view the other method would be preferable. Ultimately, the choice depends on the study design. We used $p < 0.001$ uncorrected, but we found quite large, anatomically coherent groups of voxels that are significant, therefore in statistical terms this design is not a major problem.

6.3. ROI- and VBM-based volumetry

The volumetric studies performed here using both ROI- and VBM- based techniques were never intended for determining the comparative value of these two techniques. They are of complementary importance, one to determine *in vivo* the value of ERC atrophy over that of hippocampal atrophy in MCI (**study I**), other to *in vivo* map the gray matter loss in MCI (**studies II and III**). To the best of our knowledge until **study II**, there was only one published study using VBM in MCI (Chetelat et al., 2002), but this had a slightly smaller sample and different operational criteria for MCI.

6.3.1. ROI-based volumetry (study I)

6.3.1.1. ROI-based volumetry in AD vs. controls

An imperative amount of MRI volumetric studies have been dedicated to examining MTL atrophy in AD, and our results of significantly reduced ERC and hippocampal volumes in patients with AD compared with controls are in consensus with those from the literature. Our findings revealed a 36% ERC volume loss in the AD group compared with controls, which is in agreement with an earlier study by Juottonen et al. (1998 b) where a 40% reduction of ERC

volume was found between the two studied groups. In the study by Laakso et al. (1995), the right and left hippocampal volumes decreased by 38% in patients with AD ($n=32$) compared with controls ($n=16$). Similarly, our findings revealed a 37% total hippocampal volume loss and a reduction of 36% in the right and 39% in the left hippocampus, in the AD group compared with the controls. While in our study the magnitude of the ERC changes (36%) was similar to that of the hippocampal changes (37%) in AD patients, Du et al. reported a more intense atrophy in the ERC (39%) than that in the hippocampus (27%) in the AD group (Du et al., 2001). However, the variability in measurements of ERC is greater than that of the hippocampus, and anatomical ambiguity exists when depicting the ERC boundaries on MRI, especially in the AD patients (Juottonen et al., 1999).

6.3.1.2. ROI-based volumetry in AD vs. MCI

While the interest in the MCI group of subjects increased, also the MRI volumetric studies that were dedicated to AD brought results from comparisons between the two study groups: AD and MCI. In our study, though both regions were significantly atrophied in AD patients compared with MCI subjects, significantly greater volume loss in hippocampus (32%) than that in ERC (23%) appeared in between the two groups. A study designed similarly to ours, although the criteria used for diagnosing the MCI did not exactly overlap with those proposed by the Mayo Clinic, was that conducted by Du and colleagues (2001). Yet, our results are in contrast to their findings. They claimed that, in the AD group compared with the MCI group, the ERC volume loss (30%) was significantly greater than that of the hippocampus (19%). We attribute these discrepancies to the differences in the study populations and to the variability in depicting a badly atrophied ERC on the MRI scans. Even so, our results are in agreement with the Braak&Braak staging theory (Braak and Braak, 1991 a; Braak et al., 1993), moreover they are substantiated by the results comparing the MCI and control groups. Thus, hippocampal atrophy appears to be more representative than ERC atrophy for AD.

6.3.1.3. ROI-based volumetry in MCI vs. controls

Our findings showing that compared with controls, the volumes of the ERC and hippocampus are significantly reduced in individuals with MCI, confirmed those from some earlier studies (Convit et al., 1997; Killiany et al., 2000; Xu et al., 2000; Du et al., 2001). In addition, we found that the ERC volume loss (16%) was significantly greater than the hippocampal volume

loss (8%) in MCI versus controls. This differs from the findings of another cross-sectional study (Du et al., 2001), which detected no differences in the magnitude of the volume loss between ERC (13%) and hippocampus (11%) in MCI. Our results are of interest, given that MCI refers to a transitional stage between the cognitive changes of normal aging and those of AD, and may represent a preclinical stage of AD. Therefore, our data is well in line with the assumption that the pathology of AD starts in ERC, providing *in vivo* evidence for the Braak&Braak stages (Braak and Braak, 1991 a; Braak et al., 1993). The explanation for the relatively modest average ERC volume loss (16%) may be that the MCI subjects were derived from a population-based cohort, and not from a group of individuals seeking help for memory problems. It should be noted that mildly impaired non-demented subjects form a heterogeneous group that includes both stable subjects and subjects who will develop AD (Petersen et al., 1995; Petersen et al., 1999; Petersen et al., 2001 a), as well as subjects that will possibly revert to normal (Larrieu et al., 2002).

6.3.2. VBM-based volumetry in MCI vs. controls (study II & III)

The findings from this thesis when mapping the gray matter loss in MCI subjects are in accordance with the one previously published study (Chetelat et al., 2002), using VBM in MCI, but with a slightly smaller sample and different operational criteria for MCI. Their data reported bilateral thalamic atrophy and some atrophy in the temporal neocortex. Moreover, we found a small area of atrophy in the anterior cingulate cortex. This is of interest because in animal models of AD, it is claimed that the entorhinal lesions possibly the initial site of AD pathology, lead to hypometabolism of the cingulum (Meguro et al., 1999). In addition, in humans, it should be noted that hypoperfusion of the cingulate has been proposed to predict conversion from MCI to AD (Huang et al., 2002).

The thalamic involvement noted in our study is also a matter of debate in the literature. While some VBM studies on AD have not detected thalamic involvement (Ohnishi et al., 2001; Good et al., 2002), there are positive studies as well (Baron et al., 2001; Karas et al., 2003). More recently, VBM analyses have found some thalamic involvement also in MCI (Karas et al., 2004; Chetelat et al., 2005). Our finding of thalamic involvement in MCI subjects (**study II**), was proved to rather appear in carriers of the APOE ϵ 4 allele (**study III**). In a study of cognitively normal subjects with a family history of probable AD, Reiman and colleagues concluded that compared to noncarriers, APOE ϵ 4 carriers had lower cerebral metabolic rates

for glucose (CMRgl) in the thalamus, besides other regions already proved to be affected in AD (Reiman et al., 2001). Additionally, it has been proposed that a disconnection mechanism from the MTL could lie behind the early thalamic metabolic deficit, which may be responsible for the atrophy process (Nestor et al., 2004). Moreover, the pathology of AD has been suggested to affect also the thalamus (Braak and Braak, 1991 c), yet this issue, and the factors underlying the discrepancy, remain to be resolved in future studies. One possibility that is worth mentioning is the bias inherent in the method. As Karas et al. stated the thalamus is one of the structures, which "lie geographically in locations which are hard to evaluate with computational models" (Karas et al., 2003).

An intense atrophy was present in the hippocampus-amygdala region, especially for the carriers of the APOE ϵ 4 allele in MCI subjects, where amygdala atrophy was affected bilaterally. Although according to volumetric studies, the amygdala is not a primary region affected in AD, ROI-based MRI studies (Cuénod et al., 1993; Boccardi et al., 2002) and some histopathological studies have detected damage in this region in AD, with pathological changes occurring mainly in the nuclei that receive or give rise to hippocampal or entorhinal projections (Vogt et al., 1990; Scott et al., 1991; Mann, 1992). Nevertheless, when studying the results in MCI/AD with the most pronounced atrophy occurring in the amygdala, one should be aware of the fact that bias may exist when using VBM, which may be greatly affected by the reduced gray/white matter contrast in old diseased subjects and the increased motion effects on the images.

6.4. Classification with ROI-based volumetry (study I)

6.4.1. Classification of AD and controls

When classifying AD patients and controls, both the hippocampal and the ERC volumes were of statistical significance. Yet, this yielded an overall classification of 90.6%, which was similar to the 90.7% classification achieved using hippocampus alone; hence the contribution of ERC was negligible. Du et al. (2001) found no significant differences in the power of ERC and that of the hippocampus in differentiating patients with AD from controls, but they improved the classification (89%) between the two groups when using a combination of both regional volumes. For the same purpose, Lehericy et al. (1994) reached 100% accuracy with combined volumes of the hippocampus and amygdala, but using the hippocampus alone they

achieved an accuracy of only 89% in the correct classification of 26 subjects. A similar power of classification (89%) was reported by Laakso and colleagues when using the hippocampus alone to differentiate between 55 AD patients and 42 controls (Laakso et al., 1998).

6.4.2. Classification of AD and MCI

Comparing the groups of AD and MCI, an overall classification of 80.5% was obtained when using hippocampus, and adding ERC to the model did not improve the classification. The only significant variable that entered into the model in a stepwise discriminant analysis was the total hippocampal volume, which yielded a classification of 82.3%. Our findings are similar to the results from the study by Dickerson et al. (2001) in classifying non-demented subjects and AD patients, but the volumetry protocol used was different from ours and non-demented subjects overlapped only partially with the MCI subjects. In the study by Killiany et al., the ERC alone gave a better accuracy in discriminating mild AD from "questionables" (81%) or from converters (85%) than did the hippocampus alone (75%, respectively 76%) (Killiany et al., 2002), though again, their ERC volumetry protocol differed considerably from ours. Comparable results were reported by Du and colleagues, presenting the volume of ERC with a greater power of discrimination than that of hippocampus (Du et al., 2001). Xu and colleagues could identify no differences in the power of ERC and hippocampal volumes in classifying the MCI and AD groups (Xu et al., 2000). The differences across structural MRI studies could be partially explained by the use of the different volumetric protocols, as well as by the criteria used for diagnosing MCI and the method to recruit the subjects.

6.4.3. Classification of MCI and controls

To prove *in vivo* that MCI is a group distinct from controls adds weight to the value of such a volumetric study. When Xu et al. (2000) failed to prove the hypothesis that MRI-derived measures of the ERC would be superior to hippocampal measures in classifying controls and MCIs, de Leon et al. (2001) stated "the hypothesis that the anatomic sequence of AD affects the EC prior to the hippocampus remains to be adequately addressed by MRI". In support of this theoretical expectance (de Leon et al., 2001), we showed that the ERC volume, but not the hippocampal volume, best discriminated MCI subjects from controls. To our knowledge, this had not been demonstrated prior to our study, using the same protocol for ERC volumetric measurements (Insausti et al., 1998) applied to MCI subjects as defined by

Petersen et al. (Petersen et al., 1995; Petersen et al., 1999). For example, there are earlier studies on the same topic, but with different protocols and diagnostic criteria, with results also favouring ERC over hippocampus. Accordingly, in the longitudinal study by Dickerson et al., the authors showed that ERC volume is better than hippocampal volume at distinguishing (69%) non-demented individuals (ND) (n=28) from controls (n=34) (Dickerson et al., 2001). However, the protocol they used for the ERC volumetric measurements (Goncharova et al., 2001) was different from ours and the concepts of ND and MCI overlap only partially. In another longitudinal study, Killiany and colleagues showed that only ERC could discriminate normals from "questionables" (83% accuracy) and from converters (84% accuracy), while the comparable discriminant analysis with the hippocampus in both cases was not significant (Killiany et al., 2002). The "questionables" and converters could not be discriminated by any of the two measured regions. For the classification of "questionables" a clinical dementia rating of 0.5 was considered and not the MCADRC criteria of MCI (Petersen et al., 1995; Petersen et al., 1999). Retrospectively shown, only a part of them met the criteria for MCI. Additionally the ERC protocol was different from ours: they measured only the midregion of the ERC from three slices of 1.5 mm thickness each.

6.5. APOE and patterns of brain atrophy in MCI (study III & IV)

The exact mechanisms by which APOE influences AD are not fully understood. Strong associations for APOE genotype with AD were shown to exist, since the APOE allele $\epsilon 4$ is the most consistently confirmed genetic risk factor for AD (Farrer et al., 1997). It was suggested that AD patients, carriers of APOE $\epsilon 4$ allele have more pronounced neuropathological changes, and exhibit more prominent atrophy of the MTL, as well as more severe memory loss compared to those AD patients with no $\epsilon 4$ allele (Petersen et al., 1995; Alberts, 1996; Lehtovirta et al., 2000; Engelborghs et al., 2003). The genetic asset (the presence of APOE $\epsilon 4$ allele) is consistent with a theory of greater brain vulnerability in $\epsilon 4$ carriers. Our results (**study III**) show that the presence of APOE $\epsilon 4$ in MCI subjects is associated with a greater volume loss in the parahippocampal gyrus, including the ERC, as well as in amygdala and in the medial dorsal thalamic nucleus. This is in a way, an association *in crescendo* observed in our MCI cohort, as it increases with the increased frequency of $\epsilon 4$ allele. In the heterozygous group for the APOE $\epsilon 4$ allele, only atrophy of parahippocampal gyrus, with ERC included, reached the level of statistical significance. As far as we are aware, this effect of the APOE $\epsilon 4$ on brain had never been previously evaluated,

using VBM-technique in MCI subjects. However, our results are of a preliminary nature, considering the small number of carriers studied, especially in the homozygous group. Nevertheless, our results, of higher frequency of the APOE $\epsilon 4$ allele associated with atrophy in the brain regions that overlap with those found to be atrophic in the total MCI group when compared to controls, are of interest considering that the APOE $\epsilon 4$ allele was shown to be a risk factor for conversion to MCI in cognitively healthy aged subjects (DeCarli et al., 2001; Tervo et al., 2004). Yet, this is just a speculation, as long as longitudinal imaging study-results on conversion to MCI in normal elderly subjects are not available now. Our results in MCI subjects, while employing the VBM-technique, resemble the dose-dependent effect of the APOE $\epsilon 4$ allele on the extent of atrophy of the MTL in AD patients, which has been detected with ROI-based volumetry and presented significantly increased atrophy from noncarriers of APOE $\epsilon 4$ allele to homozygous carriers, via heterozygous carriers (Lehtovirta et al., 1996; Juottonen et al., 1998 a; Geroldi et al., 1999; Geroldi et al., 2000).

The exact mechanism underlying the associations of APOE $\epsilon 4$ allele with the AD process is elusive. The APOE $\epsilon 4$ allele is considered to shift the age of onset of AD (Corder et al., 1993), but this was not the case in our study. In the present study (**study IV**), in the progressive MCI group, the groups of APOE did not differ in terms of age. Moreover there was no difference at baseline in the MMSE score, or CDR sum of boxes in the progressive MCI groups of APOE genotype (progressive carriers versus progressive noncarriers). However, the number of converters and accordingly the number of carriers that progressed to dementia was low in our study and this could have influenced the results achieved.

Nevertheless, the risk of APOE $\epsilon 4$ allele for AD was evident also in our sample of MCI subjects, although the APOE genotype was not a significant predictor for conversion. Thus, while for the APOE $\epsilon 4$ allele noncarriers there were no differences in MTL volumes between the progressive and stable MCI groups, for the APOE $\epsilon 4$ allele carriers the differences in MTL volumes were significant between the two groups (progressive versus stable MCI). Moreover, in the progressive MCI group, the carriers of at least one $\epsilon 4$ allele had significantly reduced hippocampus compared to noncarriers.

The functions of the APOE in brain are still not fully understood. A greater accumulation of histopathological AD hallmarks in APOE $\epsilon 4$ carriers has been proposed (see for review Cedazo-Minguez and Cowburn, 2001). In addition, in the case of a neuronal damage occurred

by different injurious agents, the needed neuronal repair of synaptodendritic connections was considered to be modulated by the presence of APOE, where the $\epsilon 4$ allele was associated with impaired cell repair and synaptic remodeling (Mahley and Rall, 2000). The plastic neuronal reorganisation, as evaluated by changes in the length and arborization of dendrites, has been shown to be impaired in AD carriers of the APOE $\epsilon 4$ allele (Arendt et al., 1997). Thus, a poor compensatory mechanism to repair neuronal damage additional to more accumulation of different histopathological AD features, might account for the more prominent brain atrophy in MCI carriers of APOE $\epsilon 4$ allele versus noncarriers, with this being even more apparent in the MCI progressive group.

6.6. Prediction of AD in MCI (study IV)

During the follow-up time of ~34 months, 13 subjects (21.7%) converted to dementia, with the annual conversion rate being 7.7% emphasizing the heterogeneity of MCI. Larrieu and colleagues in their longitudinal study found an annual conversion rate of 8.3%, but more than 40% of cases reverted to normal during 5 years of follow up (Larrieu et al., 2002). In our study, seven (12%) out of 60 MCI subjects who entered the follow-up had undergone an improvement of cognition by the last evaluation, indicative of the instability inherent in the MCI category as a diagnostic entity. MRI volumetric data in combination with neuropsychological data and APOE $\epsilon 4$ allele have shown a significant role in predicting the risk of AD (Petersen et al., 1995; Albert, 1996). In the present study, we found that the right sided volumes of the hippocampus and ERC and the CDR sum of boxes significantly predicted the progression of MCI to dementia. In contrast, the MMSE score, WML burden, or APOE genotype were not significant predictors of progression. It is well known that the ERC occupies a key position for the communication between the hippocampus and the rest of the brain. Accordingly, the degeneration of the neuronal architecture in the ERC destroys a large functional hippocampal pathway respectively causing memory impairment and cognitive deficits associated with AD (Hyman et al., 1984). Indeed, if the patients who developed non-AD dementia were excluded from our analysis, the only volumes of hippocampi and ERCs predicted the progression to AD. These findings are well in line with data reported by Korf and colleagues, showing that the visual assessment of MTL structures on MRI using a standardized rating scale is a predictor of dementia in MCI subjects independently of e.g. age, gender, education, MMSE, CDR sum of boxes, APOE genotype, and WML burden (Korf et al., 2004).

It has been proposed that the WML burden is associated with cerebrovascular or vascular phenomena (Laurer, 2003). Additionally, vascular risk factors have been shown to be associated with increased risk for AD and MCI (Kivipelto et al., 2001; Kivipelto et al., 2002; Tervo et al., 2004). Moreover, there are suggestions that WMLs could contribute to the dementia process by accelerating the cognitive decline in MCI subjects (Wolf et al., 2000). Nevertheless, we found no association between WMLs and progression of MCI to dementia in this population-based cohort. The extent of the WML burden was relatively modest, which may be explained by the criteria of MCI used in this study emphasizing the memory loss. However, also other studies have indicated that atrophy of MTL structures is a stronger predictor of dementia than the amount of WMLs (Korf et al., 2004).

6.7. Future studies

Studies on brain with different MR techniques are important to be applied in the future on even larger database of MCI subjects formed in the limit of possibility to please both, the objectives and the technical factors implicated in the study protocols. This is of importance to further on map the brain in MCI subjects, to try to predict conversion to dementia/AD and to determine what the best techniques to apply for those reasons are, from different points of view: grade of technical difficulty, cost level and time consuming.

A large post-mortem study-design including histopathological diagnosis and *in vivo* imaging volumetry measurements, as well as *in vivo* brain mapping findings would provide reliability of neuroimaging results and add differential diagnostic value in what concerns dementia investigations with high implications in the treatment of dementia. In the coming years visualization of neuropathological features such as beta-amyloid accumulation and even earlier events in the the pathogenesis of AD using either PET or MRI will be a great challenge. In addition, new techniques such as diffusion tensor imaging and arterial spin labelling are worth for further studies.

Neuroimaging should be of an imperative value when used in drug trials to investigate rates of atrophy and changes in brain during a specific treatment, with high implications in monitoring the prognosis and outcome in MCI cohorts and in AD patients. Rates of brain atrophy and ventricular dilatation are of interest in longitudinal studies and useful in drug

trials in MCI and AD cohorts. For the evaluation of the brain tissue in clinical trials importance should be given to both the global brain rates of atrophy and the MTL rates of atrophy, possibly with accent on ERC and hippocampus.

7. CONCLUSIONS

In conclusion, the strength of the present study is the large size of the MCI sample derived from population-based cohorts. Volumetric MRI analysis of the ERC and hippocampus provided *in vivo* evidence that ERC atrophy precedes hippocampal atrophy in AD. In the MCI subjects, involvement of other brain areas in addition to the MTL was also present. The novelty of this work, compared to previous research done in MCI subjects, is the examination of the effects of the APOE $\epsilon 4$ allele on brain morphology in MCI using the VBM method. An annual conversion rate of 7.7% from MCI to dementia over a follow-up of 34 months was observed. Prediction of conversion to AD was acquired with the atrophy of the MTL. The APOE $\epsilon 4$ allele, although not a predictor of progression to dementia, does seem to modulate neurodegeneration, by increasing brain susceptibility to the effects of the disease. MRI volumetry remains a useful tool in identifying the anatomical markers for incipient AD.

In summary:

- 1). The ERC volume loss was dominant over the hippocampal volume loss in MCI, whereas more pronounced hippocampal volume loss appeared in mild AD.
- 2). Volumetric measurements of the ERC were more powerful than those of the hippocampus in discriminating MCI subjects from controls.
- 3). Mapping the GM loss with VBM in MCI, the involvement of other brain areas in addition to the MTL was found: left superior parietal lobule, left cingulate gyrus and, notably, the thalami bilaterally.
- 4). The vast majority of the brain atrophy observed at the group level in MCI appears to be due to the small group homozygous for the $\epsilon 4$ allele.
- 5). Atrophy of the ERC and hippocampus, mostly on the right side, predicted the conversion to AD.
- 6). The CDR score, WML load or ApoE genotyping provided no additional value over that of the MTL atrophy in the prediction of progression of MCI to AD.

8. REFERENCES

Alberts MS. Cognitive and neurobiologic markers of early Alzheimer disease. *Proc Natl Acad Sci USA* 1996;93:13547-13551.

Alexopoulos P, Grimmer T, Pernecky R, Domes G, Kurz A. Do all patients with mild cognitive impairment progress to dementia? *J Am Geriatr Soc* 2006;54:1008-1010 a.

Alexopoulos P, Grimmer T, Pernecky R, Domes G, Kurz A. Progression to dementia in clinical subtypes of mild cognitive impairment. *Dement Geriatr Cogn Disord* 2006;22:27-34 b.

Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde. *Allgem Z Psychiatr Psych-Gerish Med* 1907;64:146-148.

Alzheimer A. Über eigenartige Krankheitsfälle des späteren Alters. *Z Gesamte neurol Psychiatr* 1911;4:356-385. - English translation in Förstl H, Levy R. On certain peculiar diseases of old age. *Hist Psychiatry* 1991;2:71-101.

American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 3rd edn.. Washington DC: American Psychiatric Association, 1980.

American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 3rd edn., revised. Washington DC: American Psychiatric Association, 1987.

American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*. 4th edn.. Washington DC: American Psychiatric Association, 1994.

Arendt T, Schindler C, Bruckner MK, Eschrich K, Bigl V, Zendlick D, Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. *J Neurosci* 1997;15:516-529.

Arriagada PV, Grwdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 1992;42:631-639.

Ashburner J, Friston KJ. Voxel-based morphometry - the methods. *Neuroimage* 2000;11:805-821.

Ashburner J, Friston KJ. Why voxel-based morphometry should be used. *NeuroImage* 2001;14:1238-1243.

Ashburner J, Csernansky JG, Davatzikos C, Fox NC, Frisoni GB, Thompson PM. Computer-assisted imaging to assess brain structure in healthy and diseased brains. *Lancet Neurol* 2003;2:79-88.

Au R, Massaro J, Wolf PA, Young ME, Beiser A, Seshadri S, D'Agostino RB, DeCarli C. Association of White Matter Hyperintensity Volume With Decreased Cognitive Functioning. The Framingham Heart Study. *Arch Neurol* 2006;63:246-250.

Baron JC, Chetelat G, Desgranges B, Perchey G, Landeau B, de la Sayette V, Eustache F. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. *NeuroImage* 2001;14:298-309.

Bell-McGinty S, Lopez OL, Meltzer CC, Scanlon JM, Whyte EM, DeKosky ST, Becker JT. Differential Cortical Atrophy in Subgroups of Mild Cognitive Impairment. *Arch Neurol* 2005;62:1393-1397.

Berg L. Clinical dementia rating (CDR). *Psychopharmacol Bull* 1988;24:637-639.

Bhatia S, Bookheimer SY, Gaillard WD, Theodor WH. Measurement of whole temporal lobe and hippocampus for MR volumetry: normative data. *Neurology* 1993;43:2006-2010.

Black SE. The search for diagnostic and progression markers in AD. *Neurology* 1999;52:1533-1534.

Bobinski M, de Leon MJ, Wegiel J, DeSanti S, Convit A, Saint Louis LA, Rusinek H, Wisniewski HM. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. *Neuroscience* 2000;95:721-725.

Boccardi M, Pennanen C, Laakso MP, Testa C, Geroldi C, Soininen H, Frisoni GB. Amygdaloid atrophy in frontotemporal dementia and Alzheimer's disease. *Neurosci Lett* 2002;335:139-143.

Boccardi M, Sabattoli F, Testa C, Beltramello A, Soininen H, Frisoni GB. APOE modulation of Alzheimer's and frontotemporal dementia. *Neurosci Lett* 2004;356:167-170.

Borkowski JG, Benton AL and Spreen O. Word fluency and brain damage. *Neuropsychologia* 1967;5:135-140.

Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol (Berl)* 1991;82:239-259 a.

Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. *Brain Pathol* 1991;1:213-216 b.

Braak H, Braak E. Alzheimer's disease affects limbic nuclei of the thalamus. *Acta Neuropathol* 1991;81:261-268 c.

Braak H, Braak E and Bohl J. Staging of Alzheimer-related cortical destruction. *Eur Neurol* 1993;33:403-408.

Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiol Aging* 1995;16:271-284.

Busatto GF, Garrido GEJ, Almeida OP, Castro CC, Camargo CHP, Cid CG, Buchpiguel CA, Furuie S, Bottino CM. A voxel-based morphometry study of temporal lobe gray matter reductions in Alzheimer's disease. *Neurobiol Aging* 2003;24:221-231.

- Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. *Neurology* 1974;24:1019–1025.
- Butters N, Granholm E, Salmon DP and Grant I. Episodic and semantic memory: a comparison of amnesic and demented patients. *J Clin Exp Neuropsychol* 1987;9:479–497.
- Callen DJ, Black SE, Gao F, Caldwell CB, Szalai JP. Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. *Neurology* 2001;57:1669-1674.
- Cedazo-Miguez A, Cowburn RF. Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. *J Cell Mol Med* 2001;5:254-266.
- Chen R, Herskovits EH. Network analysis of mild cognitive impairment. *Neuroimage* 2006;29:1252-1259.
- Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron J-C. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. *Neuroreport* 2002;13:1939-1943.
- Chetelat G and Baron J-C. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. *NeuroImage* 2003;18:525-541.
- Chetelat G, Landeau B, Eustache F, Mezenghe F, Viader F, De La Sayette V, Desgranges B, and Baron J-C. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study. *NeuroImage* 2005;27:934-946.
- Coffey CE, Wilkinson WE, Parashos IA, Soady SA, Sullivan RJ, Patterson LJ, Figiel GS, Webb MC, Spitzer CE, Djang WT. Quantitative cerebral anatomy of the aging human brain: a cross-sectional study using magnetic resonance imaging. *Neurology* 1992;42:527-536.
- Corder EH, Saunders AM, Strimatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 1993;261:921-923.
- Convit A, de Leon MJ, Hoptman MJ, Tarshish C, De Santi S, Rusinek H. Age-related changes in the brain: I. Magnetic resonance imaging measures of temporal lobe volumes in normal subjects. *Psychiatr Q* 1995;66:343-355.
- Convit A, de Leon MJ, Tarshish C, De Santi S, Tsui W, Rusinek H and George A. Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. *Neurobiol Aging* 1997;18:131-138.
- Crook T, Bartus RT, Ferris SH, Whitehouse P, Cohen GD, and Gershon S. Age-associated memory impairment: proposed diagnostic criteria and measures of clinical change - report of a National Institute of Mental Health Work Group. *Devel Neuropsychol* 1986;2:261-276.
- Cuénod CA, Denys A, Michot J-L, Jehenson P, Forette F, Kaplan D, Syrota A, Boller F. Amygdala atrophy in Alzheimer's disease: an in vivo magnetic resonance imaging study. *Arch Neurol* 1993;50:941–945.

- Cummings JL, Benson DF. Dementia of the Alzheimer type: an inventory of the diagnostic clinical features. *J Am Geriatric Soc* 1986;34:12-19.
- DeCarli C, Murphy DG, Gillette JA, Haxby JV, Teichberg D, Schapiro MB, Horwitz B. Lack of age-related differences in temporal lobe volume of very healthy adults. *AJNR Am J Neuroradiol* 1994;15:689-696.
- DeCarli C, Murphy DG, Tranh M, Grady CL, Haxby JV, Gillette JA, Salerno JA, Gonzales-Aviles A, Horvitz B and Rapoport SI. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. *Neurology* 1995;45:2077-2084.
- DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and Brain Morphologic Correlates of Mild Cognitive Impairment in the National Heart, Lung, and Blood Institute Twin Study. *Arch Neurol* 2001;58:643-647.
- de Leon M, Bobinski M, Convit A, Wolf O and Insausti R. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. *Neurology* 2001;56:820–821.
- Dementia. Council on Scientific Affairs. *JAMA* 1986;256:2234-2238.
- Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Benett DA, Beckett LA, deToledo-Morell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. *Neurobiology of Aging* 2001;22:747-754.
- Dickerson BC and Sperling RA. Neuroimaging Biomarkers for Clinical Trials of Disease-Modifying Therapies in Alzheimer's Disease. *NeuroRx* 2005;2:348-360.
- Du AT, Schuff N, Amend D, Laakso MP, Hsu YY, Jagust WJ, Yaffe K, Kramer JH, Reed B, Norman D, Chui HC, Weiner MW. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2001;71:441-447.
- Duvernoy HM. *The Human Brain: Surface, Three-Dimensional Sectional Anatomy with MRI, and Blood Supply*. SpringerWienNewYork, 1999.
- Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den Broeck M, Serneels S, Cruts M, Van Broeckhoven C, De Deyn PP. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. *J Neurol Neurosurg Psychiatry* 2003;74:1148-1151.
- Erkinjuntti T, Wikström J, Palo J, Autio L. Dementia among medical inpatients: Evaluation of 2000 consecutive admissions. *Arch Intern Med* 1986;146:1923-1926.
- Erten-Lyons D, Howieson D, Moore MM, Quinn J, Sexton G, Silbert L, Kaye J. Brain volume loss in MCI predicts dementia. *Neurology* 2006;66:233-235.
- Evans AC, Kamber M, Collins DL, McDonald D. An MRI-based probabilistic atlas of neuroanatomy. In: Shorvon S, Fish D, Andermann F, Bydder GM, Stefan H (Eds). *Magnetic resonance scanning and epilepsy*. New York: Plenum Press 1994:263–274.

Ezekiel F, Chao L, Kornak J, Du AT, Cardenas V, Truran D, Jagust W, Chui H, Miller B, Yaffe K, Schuff N, Weiner M. Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer's disease: Boundary Shift Integral versus tracing of the entorhinal cortex and hippocampus. *Alzheimer Dis Assoc Disord* 2004;18:196-201.

Farlow MR, He Y, Tekin S, Xu J, Lane R and Charles HC. Impact of APOE in mild cognitive impairment. *Neurology* 2004;63:1898-1901.

Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *J Am Med Assoc* 1997;278:1349-1356.

Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DHB, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ, for the Alzheimer's Disease Cooperative Study. Sex, Apolipoprotein E ϵ 4 Status, and Hippocampal Volume in Mild Cognitive Impairment. *Arch Neurol* 2005;62:953-957.

Folstein MF, Folstein SE and McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatry Res* 1975;12:189-198.

Fox NC, Freeborough PA, Rossor MN. Visualisation and quantification of rates of atrophy in Alzheimer's disease. *Lancet* 1996;348:94-97.

Fox NC, Freeborough PA. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. *J Magn Reson Imaging* 1997;7:1069-1075.

Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. *IEEE Trans Med Imaging* 1997;16:623-629.

Frisoni GB, Laakso MP, Beltramello A, Geroldi C, Bianchetti A, Soininen H, Trabucchi M. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer's disease. *Neurology* 1999;52:91-100.

Frisoni GB, Testa C, Zorzan A, Sabattoli F, Beltramello A, Soininen H, and Laakso MP. Detection of grey matter loss in mild Alzheimer's disease with voxel-based morphometry. *J Neurol Neurosurg Psychiatry* 2002;73:657-664.

Frisoni GB, Scheltens Ph, Galluzzi S, Nobili FM, Fox NC, Robert PH, Soininen H, Wahlund LO, Waldemar G and salmon E. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral flow and metabolism: consensus paper of the EADC. *J Neurol Neurosurg Psychiatry* 2003;74:1371-1381.

Geffen G, Moar KJ, O'Hanlon AP, Clark CR, Geffen LB. Performance measures of 16- to 86-year-old males and females on the Auditory Verbal Learning Test. *Clin Neuropsychol*. 1990;4:45-63.

Geroldi C, Pihlajamäki M, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB. ApoE e4 is associated with less frontal and more medial temporal lobe atrophy in AD. *Neurology* 1999;53:1825-1832.

Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, Trabucchi M, Frisoni GB. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease. A volumetric MRI study. *J Neurol. Neurosurg Psychiatry* 2000;68:93-96.

Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer's Disease. *J Neurosci* 1996;16:4491-4500.

Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann Neurol* 1997;41:17-24.

Goncharova II, Dickerson BC, Stoub TR, deToledo-Morrell L. MRI of entorhinal cortex: a reliable protocol for volumetric measurement. *Neurobiol Aging* 2001;22:737-745.

Good CD, Johnsrude IS, Ashburner J, Henson RNA, Friston KJ, Frackowiak RSJ. A Voxel-Based Morphometric Study on Ageing in 465 Normal Adult Human Brains. *NeuroImage* 2001;14:21-36 a.

Good CD, Johnsrude I, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. Cerebral asymmetry and the effects of sex and handedness on brain structure: a voxel-based morphometric analysis of 465 normal adult human brains. *Neuroimage* 2001;14:685-700 b.

Good CD, Scahill RI, Fox NC, Ashburner J, Friston KJ, Chan D, Crum WR, Rossor MN, Frackowiak RS. Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. *NeuroImage* 2002;17:29-46.

Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Philadelphia: Lea and Febiger, 1972.

Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko H, and McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. *Lancet* 1997;349:1793-1796.

Hamos JE, DeGennaro LJ, Dracgman DA. Synaptic loss in Alzheimer's disease and other dementia. *Neurology* 1989;39:355-361.

Hay JW, Ernst RL. The economic costs of Alzheimer's disease. *Am J Public Health* 1987;77:1169-1175.

Huang C, Wahlund L-O, Svensson L, Winblad B and Julin P. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. *BMC Neurol* 2002;2:9.

Huesgen CT, Burger PC, Crain BJ and Johnson GA. In vitro MR microscopy of the hippocampus in Alzheimer's disease. *Neurology* 1993;43:145-152.

- Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. *Science* 1984;225:1168-1170.
- Hänninen T, Hallikainen M, Koivisto K, Partanen K, Laakso MP, Riekkinen PJ Sr., Soininen H. Decline of frontal lobe functions in subjects with age-associated memory impairment. *Neurology* 1997;48:148–153.
- Hänninen T, Hallikainen M, Tuomainen S, Vanhanen M and Soininen H. Prevalence of mild cognitive impairment: a population-based study in elderly subjects. *Acta Neurol Scand* 2002;106:148–154.
- Insausti R, Juottonen K, Soininen H, Insausti AM, Partanen K, Vainio P, Laakso MP, Pitkänen A. MR Volumetric Analysis of the Human Entorhinal, Perirhinal, and Temporopolar Cortices. *AJNR Am J Neuroradiol* 1998;19:659-671.
- Jack CR Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. *Radiology* 1989;172:549-554.
- Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. *Neurology* 1997;49:786-794.
- Jack CR Jr, Petersen RC, Xu YC, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Waring SC, Tangalos EG, Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. *Neurology* 1999;52:1397-1403.
- Jack CR Jr, Petersen RC, Xu Y, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Tangalos EG and Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. *Neurobiology* 2000;55:484-490.
- Jack CR Jr, Dickson DW, Parisi JE, Xu YC, Cha RH, O'Brien PC, Edland SD, Smith GE, Boeve BF, Tangalos EG, Kokmen E, Petersen RC. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. *Neurology* 2002;58:750-757.
- Jernigan TL, Press GA, Hesselink JR. Methods for measuring brain morphologic features on magnetic resonance imaging, validation and normal aging. *Arch Neurol* 1990;47:27-32.
- Jernigan TL, Archibald SL, Berhow MT, Sowell ER, Foster DS, Hesselink JR. Cerebral structures on MRI, Part I: Localization of age-related changes. *Biol Psychiatry* 1991;29:55-67.
- Juottonen K, Lehtovirta M, Helisalmi S, Riekkinen PJ Sr, Soininen H. Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E ϵ 4 allele. *J Neurol Neurosurg Psychiatry* 1998;65:322-327 a.
- Juottonen K, Laakso MP, Insausti R, Lehtovirta M, Pitkänen A, Partanen K, Soininen H. Volumes of the Entorhinal and Perirhinal Cortices in Alzheimer's Disease. *Neurobiol Aging* 1998;19:15-22 b.

Juottonen K, Laakso MP, Partanen K, Soininen H. Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer's disease. *AJNR Am J Neuroradiol* 1999;20:139-144.

Kantarci K and Jack CR Jr. Quantitative Magnetic Resonance Techniques as Surrogate Markers of Alzheimer's Disease. *NeuroRx* 2004;1:196-205.

Kaplan E, Goodglass H, Weintraub S. *The Boston Naming Test*. Philadelphia: Lea and Febiger, 1983.

Kaplan EF, Goodglass H, Weintraub S. *The Boston Naming Test*. Boston: E. Kaplan & H. Goodglass, 1991.

Karas GB, Burton EJ, Rombouts SARB, van Schijndel RA, O'Brien JT, Sceltens Ph, McKeith IG, Williams D, Ballard C, and Barkhof F. A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimised voxel-based morphometry. *NeuroImage* 2003;18:895-907.

Karas GB, Scheltens P, Rombouts SARB, Visser PJ, van Schijndel RA, Fox NC, and Barkhof F. Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. *NeuroImage* 2004;23:708-716.

Khachaturian ZS. Diagnosis of Alzheimer's disease. *Arch Neurol* 1985;42:1097-11205.

Killiany RJ, Gomez-Isla T, Moss M, Kikinis R, Sandor T, Jolesz F, Tanzi R, Jones K, Hyman BT, Albert MS. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. *Ann Neurol* 2000;47:430-439.

Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. *Neurology* 2002;58:1188-1196.

Kivipelto M, Helkala E-L, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment. A population-based study. *Neurology* 2001;56:1683-1689.

Kivipelto, M., Helkala, E.L., Laakso, M.P., Hanninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A., Soininen H.. Apolipoprotein E ϵ 4 allele, elevated midlife cholesterol and systolic blood pressure are independent risk factors for late-life Alzheimer's disease. *Ann Intern Med* 2002;137:149-55.

Kluger A, Ferris SH, Golomb J, Mittelman MS and Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. *J Geriatr Psychiatry Neurol* 1999;12:168-179.

Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC. Practice parameter: Diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001;56:1143-1153.

Knopman DS, Boeve BF, Petersen RC. Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. *Mayo Clin Proc* 2003;78:1290-1308.

Kordower JH, Chu Y, Stebbins GT, DeKosky ST, Cochran EJ, Bennett D, Mufson EJ. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. *Ann Neurol* 2001;49:202–213.

Korf ES, Wahlund L-O, Visser PJ and Scheltens P. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. *Neurology* 2004;63:94-100.

Kraepelin E. *Psychiatrie: ein Lehrbuch für Studierende und Ärzte*. Leipzig: verlag v. Johann Ambrosius Barth, 1910.

Kral VA. Senescent forgetfulness: benign and malignant. *Can Med Assoc J* 1962;86:257-260.

Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS and Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. *Neurology* 2006;66:828-832.

Laakso MP, Soininen H, Partanen K, Helkala E-L, Hartikainen P, Vainio P, Hallikainen M, Hänninen T, Riekkinen PJ Sr. Volumes of HP, amygdala and frontal lobes in the MRI-based diagnosis of early Alzheimer's disease: correlation with memory functions. *J Neural Transm Park Dis Dement Sect* 1995;9:73-86.

Laakso MP, Soininen H, Partanen K, Lehtovirta M, Hallikainen M, Hänninen T, Helkala E-L, Vainio P, and Riekkinen PJ Sr. MRI of the hippocampus in Alzheimer's disease: sensitivity, specificity, and analysis of the incorrectly classified subjects. *Neurobiol Aging* 1998;19:23–31.

Laakso MP, Lehtovirta M, Partanen K, Riekkinen PJ Sr and Soininen H. Hippocampus in Alzheimer's Disease: A 3-Year Follow-Up MRI Study. *Biol Psychiatry* 2000;47:557-561.

Larrieu S, Letenneur L, Orgogozo JM, Fabrigoule C, Amieva H, Le Carret N, Barberger-Gateau P, Dartigues JF. Incidence and outcome in mild cognitive impairment in a population-based prospective cohort. *Neurology* 2002;59:1594-1599.

Launer LJ. Epidemiology of White-Matter Lesions. *International Psychogeriatrics* 2003;15 Suppl 1:99-103.

Lehericy S, Baulac M, Chiras J, Pierot L, Martin N, Pillon B, Deweer B, Dubois B, Marsault C. Amygdalohippocampal MR volume measurements in the early stages of Alzheimer's disease. *AJNR Am J Neuroradiol* 1994;15:929-937.

Lehtovirta M, Laakso MP, Soininen H, Helisalmi S, Mannermaa A, Helkala E-L, Partanen K, Ryyänänen M, Vainio P, Hartikainen P, and Riekkinen Sr PJ. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. *Neuroscience* 1995;67:65-72.

Lehtovirta M, Soininen H, Laakso MP, Partanen K, Helisalml S, Mannermaa A, Ryyanen R, Kuikka J, Hartikainen P, Riekkinen PJ Sr. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E e4 allele. *J Neurol Neurosurg Psychiatry* 1996;60:644-649.

Lehtovirta M, Laakso MP, Frisoni GB, Soininen H. How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies, *Neurobiol Aging* 2000;21:293-300.

Levy R. Aging-associated cognitive decline. *Int Psychogeriatr* 1994;6:63-68.

Lopez OL, Jagust WJ, Dulberg C, Becker JT, DeKosky ST, Fitzpatrick A, Breitner J, Lyketsos C, Jones B, Kawas C, Carlson M, Kuller LH. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. *Arch Neurol*. 2003;60:1394-1399.

Mahley RW and Rall SC Jr. Apolipoprotein E: Far More Than a Lipid Transport Protein. *Annu Rev Genomics Hum Genet* 2000;1:507-537.

Mann DM. The topographic distribution of brain atrophy in Alzheimer's disease. *Acta Neuropathol (Berlin)* 1991;83:81-86.

Mann DMA. The neuropathology of the amygdala in ageing and in dementia; in Aggleton JP (ed): *The Amygdala: Neurobiological Aspects of Emotion, Memory and Mental Dysfunction*. New York, Wiley-Liss 1992;575-593.

Masdeu JC, Zibieta JL, Arbizu J. Neuroimaging as a marker of the onset and progression of Alzheimer's disease. *J Neurol Sci* 2005;236:55-64.

Maurer K, Volk S, Gerbaldo H, Auguste D. and Alzheimer's disease. *Lancet* 1997;349:1546-1549.

McKahn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984;34:939-944.

Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC and Chavoix C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. *Brain* 1999;122:1519-1531.

Miller AKH, Alstone RL, Corsellis JAN. Variations with age in the volumes of gray and white matter in the cerebral hemispheres of man: measurements with an image analyser. *Neuropathol Appl Neurology* 1980;6:119-132.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991;41:479-486.

- Mitrushina M, Satz P, Chervinsky A, D'Elia L. Performance of four age groups of normal elderly on the Rey Auditory-Verbal Learning Test. *J Clin Psychol*. 1991;47:351-357.
- Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. *Curr Alzheimer Res* 2006;3:161-170.
- Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology* 1989;39:1159-1165.
- Möller H-J, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. *Eur Arch Psychiatry Clin Neurosci* 1998;248:111-122.
- Nelson HE. A modified card sorting test sensitive to frontal lobe defects. *Cortex* 1976;12:313-324.
- Nestor PJ, Fryer TD, Smielewski P, and Hodges JR. Limbic Hypometabolism in Alzheimer's Disease and Mild Cognitive Impairment. *Ann Neurol* 2003;54:343-351.
- Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. *Nat Med* 2004;10(suppl):34-41.
- Neuroimaging Work Group, Alzheimer's Association. Consensus Report: The use of MRI and PET for clinical diagnosis of dementia and investigation of cognitive impairment. April 2004. Available at http://www.alz.org/Research/Papers/Imaging_consensus_report.pdf
- NIA. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. *Neurobiol Aging* 1997;18:S1-2.
- O'Brien JT, Desmond P, Ames D, Schweitzer I, Tress B. Magnetic resonance imaging correlates of memory impairment in the healthy elderly: association with medial temporal lobe atrophy but not white matter lesions. *Int J Geriatr Psychiatry* 1997;12:369-374.
- Ohnishi T, Matsuda H, Tabira T, Asada T, and Uno M. Changes in Brain Morphology in Alzheimer Disease and Normal Aging: Is Alzheimer Disease an Exaggerated Aging Process? *AJNR Am J Neuroradiol* 2001;22:1680-1685.
- Petersen RC, Smith G, Kokmen E, Ivnik RJ, Tangalos EG. Memory function in normal aging. *Neurology* 1992;42:396-401.
- Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaïd DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. *J Am Med Assoc* 1995;273:1274-8.
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG and Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch. Neurol* 1999;56:303-308.

- Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001;56:1133-1142 a.
- Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. *Arch Neurol* 2001;58:1985-1992 b.
- Petersen RC (ed.). *Mild Cognitive Impairment. Aging to Alzheimer's Disease*. Oxford University Press, 2003.
- Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. *Arch Neurol* 1994;51:874-887.
- Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili J, Scheltens Ph, Vellas B and Touchon J. Mild Cognitive Impairment in medical practice: critical review of the concept and new diagnostic procedure. Report of the MCI working group of the European Consortium on Alzheimer's disease (EADC). *J Neurol Neurosurg Psychiatry* 2006;77:714-718.
- Raz N, Gunning FM, Head D, Dupuis JH, McQuain J, Briggs SD, Loken WJ, Thornton AE, Acker JD. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. *Cereb Cortex* 1997;7:268-282.
- Raz N, Rodrigue KM, Head D, Kennedy KM, Acker JD. Differential aging of the medial temporal lobe. *Neurology* 2004;62:433-438.
- Raz N, Lindenbergh U, Rodrigue KM, Kennedy KM, Head D, Williamson A, Dahle C, Gerstorf D, Acker JD. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. *Cereb Cortex* 2005;15:1676-1689.
- Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. *Proc Natl Acad Sci USA* 2001;98:3334-3339.
- Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. *Percept Mot Skills* 1958;8:271-276.
- Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. *Neurology* 2001;56:37-42.
- Rorden C, Brett M. Stereotaxic display of brain lesions. *Behav Neurol* 2001;112:191-200.
- Rowe JW, Kahn RL. Human aging: usual and successful. *Science* 1987;237:143-149.
- Russel E. A multiple scoring method for the assessment of complex memory functions. *J Cons Clin Psychol* 1975;43:800-809.

Saunders AM, Trowers MK, Shimkets RA, Blakemore S, Crowther DJ, Mansfield TA, Wallace DM, Strittmatter WJ, Roses AD. The role of apolipoprotein E in Alzheimer's disease: pharmacogenomic target selection. *Biochimica et Biophysica Acta* 2000;1502:85-94.

Scheltens Ph, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steiling M, Wolters EC, Valk J. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal aging: diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry* 1992;55:967-972.

Scheltens Ph, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. *J Neurol* 1995;242:557-560.

Schott JM, Price SL, Frost C, Whitwell JL, Rossor MN and Fox NC. Measuring atrophy in Alzheimer's disease: a serial MRI study over 6 and 12 months. *Neurology* 2005;65:119-124.

Scott SA, DeKosky ST, Scheff SW. Volumetric atrophy of the amygdala in Alzheimer's disease: quantitative serial reconstruction. *Neurology* 1991;41:351-356.

Small GW, Jarvik LF. The dementia syndrome. *Lancet* 1982;2:1443-1446.

Smith GE, Petersen RC, Parisi JE, Ivnik RJ, Kokmen E, Tangalos EG, Waring S. Definition, course, and outcome of mild cognitive impairment. *Aging Neuropsychol Cogn* 1996;3:141-147.

Stoub TR, Bulgakova M, Leurgans S, Bennet DA, Fleishman D, Turner DA, deToledo-Morrell L. MRI predictors of risk of incident Alzheimer's disease. A longitudinal study. *Neurology* 2005;64:1520-1524.

Sullivan EV, Marsh L, Mathalon DH, Lim KO, Pfefferbaum A. Age-related decline in MRI volumes of temporal lobe gray matter but not hippocampus. *Neurobiol Aging* 1995;16:591-606.

Terry RD, Katzman R, Bick KL, Sisodia SS. *Alzheimer Disease*. 2nd edn. Lippincott Williams & Wilkins, Philadelphia, 1999.

Tervo S, Kivipelto M, Hanninen T, Vanhanen M, Hallikainen M, Mannermaa A, Soininen H. Incidence and risk factors for mild cognitive impairment: a population-based three-year follow-up study of cognitively healthy elderly subjects. *Dement Geriatr Cogn Disord* 2004;17:196-203.

Thal DR, Del Tradici K, Braak H. Neurodegeneration in normal brain aging and disease. *Sci Aging Knowledge Environ* 2004;2004:26.

Tisserand DJ, Pruessner JC, Sanz Argita EJ, van Boxtel MPJ, Evans AC, Jolles J, Uylings HB. Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry. *Neuroimage* 2002;17:657-669.

Tisserand DJ, van Boxtel MPJ, Pruessner JC, Evans AC, Jolles J. A Voxel-Based Morphometric Study to Determine Individual Differences in Gray Matter Density Associated with Age and Cognitive Change Over Time. *Cerebral Cortex* 2004;14:966-973.

Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T. Determination by PCR-RFLP of apo E genotype in a Japanese population. *J Lab Clin Med* 1993;121:598-602.

Van Hoesen GW, and Hyman BT. Hippocampal formation: anatomy and the patterns of pathology in Alzheimer's disease. *Prog Brain res* 1990;83:445-457.

Van Hoesen GW, Hyman BT, Damasio AR. Entorhinal cortex pathology in Alzheimer's disease. *Hippocampus* 1991;1:1-8.

Vogt LJK, Human BT, Van Hoesen GW, Damasio AR. Pathological alterations in the amygdala in Alzheimer's disease. *Neuroscience* 1990;37:377-385.

Wahlund LO, Julin P, Lindqvist J, Scheltens P. Visual assessment of medial temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. *Psychiatry Res* 1999;90:193-199.

Wahlund LO, Julin P, Johansson SE and Scheltens P. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. *J Neurol Neurosurg Psychiatry* 2000;69:630-635.

Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjogren M, Wallin A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P; European Task Force on Age-related White Matter Changes. A new rating scale for age-related white matter changes applicable to MRI and CT. *Stroke* 2001;32:1318-1322.

Wang PN, Lirng JF, Chang FC, Liu HC. Prediction of Alzheimer's disease in mild cognitive impairment: A prospective study in Taiwan. *Neurobiology of aging* 2006;27:1797-1806.

Wechsler D. Wechsler Adult Intelligence Scale-Revised. Cleveland: Psychological Corporation, 1981.

Wechsler D. Wechsler Memory Scale-Revised manual. San Antonio, TX: The Psychological Corporation, 1987.

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jern A, Ritchie K, van Duijn C, Visser P, Petersen RC. Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. *J Intern Med* 2004;256:240-246.

Wolf H, Ecke GM, Bettin S, Dietrich J and Gertz H-J. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. *Int J Geriatr Psychiatry* 2000;15:803-812.

Wolf H, Jelic V, Gertz H-J, Nordberg A, Julin P, Wahlund L-O. A critical discussion of the role of neuroimaging in mild cognitive impairment. *Acta Neurol Scand* 2003;107:52-76.

Xu Y, Jack CR Jr, O'Brien PC, Kokmen E, Smith GE, Invik RJ, Boeve BF, Tangalos RG, Petersen RC. Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. *Neurology* 2000;54:1760-1767.

Yaffe K, Petersen RC, Lindquist K, Kramer J, Miller B. Subtype of Mild Cognitive Impairment and Progression to Dementia and Death. *Dement Geriatr Cogn Disord* 2006;22:312-319.

Zamrini E, DeSanti S, Tolar M. Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. *Neurobiology of Aging* 2004;25:685-691.

APPENDIX: ORIGINAL PUBLICATIONS I-IV

I

**HIPPOCAMPUS AND ENTORHINAL CORTEX IN MILD COGNITIVE IMPAIRMENT
AND EARLY AD**

Neurobiology of Aging

25: 303-310, 2004

by

Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hänninen T, Laakso MP, Hallikainen M,
Vanhanen M, Nissinen A, Helkala E-L, Vainio P, Vanninen R, Partanen K, Soininen H

Reprinted with the permission from Elsevier Science

II

A VOXEL BASED MORPHOMETRY STUDY ON MILD COGNITIVE IMPAIRMENT

J Neurol Neurosurg Psychiatry

76: 11-14, 2005

by

Pennanen C, Testa C, Laakso MP, Hallikainen M, Helkala E-L, Hänninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H

Reprinted with the permission from the BMJ Publishing Group

III

**THE EFFECT OF APOLIPOPROTEIN POLYMORPHISM ON BRAIN IN MILD
COGNITIVE IMPAIRMENT: A VOXEL-BASED MORPHOMETRIC STUDY**

Dement Geriatr Cogn Disord

22: 60-66, 2006

by

Pennanen C, Testa C, Boccardi M, Laakso MP, Hallikainen M, Helkala EL, Hänninen T, Kivipelto M, Könönen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H

Reprinted with the permission from S. Karger AG, Basel

IV

**MRI OF HIPPOCAMPUS AND ENTORHINAL CORTEX IN MILD COGNITIVE
IMPAIRMENT: A FOLLOW-UP STUDY**

Neurobiology of Aging

Accepted for publication

by

Tapiola T, Pennanen C, Tapiola M, Tervo S, Kivipelto M, Hänninen T, Pihlajamäki M, Laakso MP,
Hallikainen M, Hämäläinen A, Vanhanen M, Helkala E-L, Vanninen R, Nissinen A, Rossi R,
Frisoni G, Soininen H

Reprinted with the permission from Elsevier Science

PUBLICATIONS

SERIES OF REPORTS, DEPARTMENT OF NEUROLOGY

1. **Juhani Partanen (1978):** Time-locked phenomena of human motor unit potentials. An electromyographic study of satellites and doubles.
2. **Eeva Leino (1981):** Clinical and biochemical studies on progressive myoclonus epilepsy.
3. **Hilkka Soininen (1981):** Senile dementia. A clinical, neurochemical and etiological study.
4. **Rolf Danner (1982):** Adverse effects of anticonvulsive treatment on peripheral nerve conduction and posterior dominant EEG rhythm.
5. **Markku Saksa (1982):** The autonomic nervous system in experimental allergic neuritis. A functional, morphological and biochemical study.
6. **Juhani Sivenius (1982):** Studies on the rehabilitation, epidemiology and clinical features of stroke in East Central Finland.
7. **Asla Pitkänen (1987):** Somatostatin in epilepsy. An experimental and clinical study.
8. **Esa Mervaala (1987):** Evoked potential in human epilepsy. A neurophysiological study.
9. **Kari Reinikainen (1988):** Neurotransmitters in Alzheimer's disease.
10. **Tapani Keränen (1988):** Epilepsy in adults. An epidemiologic study in Eastern Finland.
11. **Jukka Jolkkonen (1988):** Vasopressin in the central nervous system. A study based on cerebrospinal fluid measurements.
12. **Jouni Sirviö (1989):** The cholinergic system in ageing and dementia. With special reference to acetylcholinesterase.
13. **Hannu Koponen (1989):** Delirium in the elderly. A clinical, neurochemical, neuropsychological and neuroradiological study.
14. **Asla Pitkänen (1989):** Somatostatin in experimental and human epilepsy.
15. **Eeva-Liisa Helkala (1990):** Memory in patients with Alzheimer's disease and demented patients with Parkinson's disease.
16. -
17. **Paavo Riekkinen Jr (1990):** Animal models of age-related degeneration of subcortical regulatory systems. With special reference to cholinergic, noradrenergic and serotonergic systems.
18. **Toivo Halonen (1990):** Neurotransmitter amino acids in epileptic convulsions and during vigabatrin treatment.
19. **Ulla Lepola (1990):** Panic disorder. A clinical, neurochemical, neuropsychological, and neuroradiological study.
20. **Kari Murros (1991):** Stress reactions of brain infarction. A prospective study on 105 patients with acute ischemic brain infarction of internal carotid artery territory.
21. **Aarne Ylinen (1991):** Hippocampal reactions and their pharmacotherapy in experimental epilepsy.
22. **Antti Valjakka (1992):** The subcortical deafferentation of the hippocampus and noradrenergic lesions as experimental models of dementia. Hippocampal electrophysiology.
23. **Aimo Rissanen (1992):** Cerebrovascular disease in the Jyväskylä region, Central Finland.
24. **Reetta Kälviäinen (1992):** Newly diagnosed epileptic seizure disorder in adults. A prospective follow-up study on 100 patients.
25. **Maria Mazurkiewicz (1992):** The effects of the enhanced GABAergic transmission on cognitive functions: An experimental study.
26. **Pekka Jäkälä (1992):** Modulation of attention and working memory by noradrenergic, serotonergic and cholinergic systems. An experimental neuropsychopharmacological study.
27. **Kari Alhainen (1992):** Anticholinesterase drug, tacrine (THA), in Alzheimer's disease. Discrimination of responders and nonresponders.
28. **Riitta Miettinen (1993):** Inhibitory circuits and subcortical innervation of the rat hippocampus: Implications for normal function and pathophysiological processes.
29. **Hannele Lahtinen (1993):** Hippocampus in experimental models of temporal lobe epilepsy. Amino acid-mediated neurotransmission and nerve cell injury following the transection of fimbria-fornix and the electrical stimulation of perforant pathway in rat.
30. **Päivi Hartikainen (1994):** Normal ageing. A neurochemical, neurophysiological and neuropsychological study with special reference to Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
31. **Outi Heinonen (1994):** Neuropathologic and peripheral markers of Alzheimer's disease with special emphasis on β -amyloid accumulation.

32. **Minna Riekkinen (1994):** The interactions between cholinergic and serotonergic systems in the modulation of spatial navigation and passive avoidance behavior. An experimental neuropsychopharmacological study.
33. **Keijo Koivisto (1995):** Population-based dementia screening program in the city of Kuopio, Eastern Finland: Evaluation of screening methods, prevalence of dementia and dementia subtypes.
34. **Arja Tuunainen (1995):** Evaluation of epileptic patients for temporal lobe surgery and postoperative follow-up. An electrophysiological study with neuropsychological, psychiatric and clinical correlates.
35. **Mervi Pitkänen (1995):** The role and pharmacological modulation of the NMDA receptor/channel on hippocampal synaptic transmission and behavior.
36. **Olli Kosunen (1996):** A neuropathologic study on Alzheimer's disease with a special emphasis on diagnostic accuracy.
37. **Mikko Laakso (1996):** MRI of hippocampus in incipient Alzheimer's disease.
38. **Maarit Lehtovirta (1996):** Familial Alzheimer's disease. A clinical and molecular genetic study.
39. **Tuomo Hänninen (1996):** Age-associated memory impairment. A neuropsychological and epidemiological study.
40. **Vesa Savander (1997):** Organization of intrinsic connections in the rat amygdaloid complex with special emphasis on the lateral, basal and accessory basal nuclei.
41. **Heikki Sorvari (1997):** Neurons containing calcium-binding proteins in the human amygdaloid complex.
42. **Tiina Kotti (1997):** Excitotoxicity-induced neuropathological changes in the rodent hippocampus. Possible functional consequences and drug treatments.
43. **Sirja Ruotsalainen (1997):** Serotonergic system and its interactions with cholinergic receptor mediated mechanisms in the modulation of working memory. An experimental study.
44. **Seppo Helisalmi (1998):** Molecular genetics of Alzheimer's disease with special emphasis on presenilin, amyloid beta precursor protein and apolipoprotein E genes.
45. **Merja Hallikainen (1998):** Age-associated memory impairment, and apolipoprotein E. A population-based clinical, neuropsychological, neurophysiological and neuroimaging study.
46. **Matti Vanhanen (1998):** Cognitive function in glucose intolerance in the elderly: the role of hyperinsulinemia.
47. **Kirsi Juottonen (1998):** MRI-volumes of the entorhinal, perirhinal and temporopolar cortices in normal aging and in Alzheimer's disease.
48. **Raimo Pussinen (1999):** An experimental study on the role of α_1 -adrenoceptors and putrescine in the modulation of hippocampal plasticity and memory encoding - interactions with NMDA receptors.
49. **Tarja Puumala (1999):** Monoamines in the modulation of attention and response inhibition: development of a new animal model of attention deficit and impulsivity.
50. **Mia Mikkonen (1999):** The human entorhinal cortex. Anatomic organization and its alteration in Alzheimer's disease and temporal lobe epilepsy.
51. **Jukka Puoliväli (2000):** An experimental study on the cholinergic modulation of cortical arousal and cognitive functions. With special emphasis on apolipoprotein E.
52. **Kauko Pitkänen (2000):** Stroke rehabilitation in the elderly. A controlled study of the effectiveness and costs of a multidimensional intervention.
53. **Mikko Hiltunen (2000):** A molecular genetic study of factors involved in Alzheimer's disease.
54. **Sami Ikonen (2001):** The role of the septohippocampal cholinergic system in cognitive functions.
55. **Tuuli Salmenperä (2001):** Damage in the hippocampus, amygdala, entorhinal and perirhinal cortex of adults with partial epilepsy.
56. **Zinayida Bezvenyuk (2001):** Multiple pathways of DNA disintegration during neuronal apoptosis.
57. **Tero Tapiola (2001):** Biological markers for Alzheimer's disease. With special emphasis on cerebrospinal fluid β -amyloid and tau.
58. **Kirsi Puurunen (2001):** The effects of pharmacotherapy and training on functional recovery after global and focal cerebral ischemia in rats.
59. **Maaria Ikonen (2001):** Apoptosis-associated changes in neuronal gene expression. With special emphasis on the insulin-like growth factor system.

60. **Inga Kadish (2002):** Plasticity in the entorhinal-hippocampal pathway. Influences of gene mutations and hormones.
61. **Pauliina Korhonen (2002):** Gene regulation in neuronal degeneration - Role of mSin3 and YY1 factors.
62. **Miia Kivipelto (2002):** Vascular risk factors in Alzheimer's disease and mild cognitive impairment. A longitudinal, population-based study.
63. **Margit Overmyer (2002):** Gliosis in relation to Alzheimer's hallmark lesions in aging and Alzheimer's disease. A postmortem immunohistochemical study.
64. **Marja Äikiä (2002):** Verbal memory in newly diagnosed partial epilepsy. A neuropsychological study.
65. **Li Liu (2003):** Cholinergic neurotransmission, amyloid- β peptide and the pathogenesis of Alzheimer's Disease. A study in the APP and PS1 double transgenic mouse model.
66. **Jun Wang (2003):** The role of A β -peptide on spatial memory, EEG, auditory evoked potentials and nicotinic cholinergic receptors in A/P transgenic mice.
67. **Juhana Aura (2003):** Interaction of muscarinic acetylcholine and N-methyl-D-aspartate -type glutamate receptors in the regulation of spatial learning and memory.
68. **Johanna Kuhmonen (2003):** Neuroprotection in experimental acute cerebral ischaemia: α 2-adrenoreceptor agonism, MAO-B inhibition, and enhancement of GABAergic neurotransmission as neuroprotective strategies.
69. **Jaana Autere (2003):** Genetics of Parkinson's Disease in the Finnish Population.
70. **Erkki Kuusisto (2004):** Role of the p62 protein in the formation of neuropathological cytoplasmic inclusions.
71. **Maija Pihlajamäki (2004):** Functional MRI studies on human declarative memory.
72. **Chuan-sheng Zhao (2005):** Psychotropic medication and functional recovery following cortical stroke in aged rats.
73. **Dimitrije Jakovljević (2005):** The roles of chronobiological and socioeconomic factors in the occurrence of cerebrovascular diseases.
74. **Sinikka Peurala (2005):** Rehabilitation of gait in chronic stroke patients.
75. **Laura Parkkinen (2005):** Impact of α -synuclein pathology on aging.
76. **Iain Wilson (2005):** Hippocampal place cells as a window into cognitive aging.
77. **Susan Iivonen (2005):** Genetic and expressional studies of Alzheimer's disease candidate genes. Emphasis on CYP19, seladin-1 and HSPG2 genes.
78. **Jouni Ihalaainen (2005):** Regulation of dopamine release in the forebrain by alpha2-adrenoceptors and NMDA glutamate receptors - a microdialysis study.
79. **Giedrius Kalesnykas (2005):** Cholinergic neurons of the rodent basal forebrain and their content of estrogen receptor alpha.
80. **Marina Boccardi (2006):** MRI studies in frontotemporal dementia.
81. **Anne Koivisto (2006):** Genetic components of late-onset Alzheimer's disease with special emphasis on ApoE, IL-6, CYP46, SERPINA3 and PPAR γ .
82. **Taneli Heikkinen (2006):** Cognitive effects of estrogen in ovariectomized, aged and transgenic mice modeling Alzheimer's disease.
83. **Minna Korolainen (2006):** Proteomic analysis of post-translationally modified proteins in Alzheimer's disease.
84. **Petri Kerokoski (2006):** Regulation of cyclin-dependent kinase 5 (Cdk5) with special emphasis on changes occurring during neuronal cell death.